Published in final edited form as:

J Org Chem. 2016 November 18; 81(22): 10809–10824. doi:10.1021/acs.joc.6b01905.

Sequential One-Pot Multienzyme (OPME) Chemoenzymatic Synthesis of Glycosphingolipid Glycans

Hai Yu^{a,b,*}, Yanhong Li^{a,b}, Jie Zeng^{b,c}, Vireak Thon^{b,†}, Dung M. Nguyen^{b,‡}, Thao Ly^b, Hui Yu Kuang^{b,±}, Alice Ngo^b, and Xi Chen^{b,*}

^aGlycohub, Inc., 4070 Truxel Road, Sacramento, CA 95834, USA

^bDepartment of Chemistry, University of California, One Shields Avenue, Davis, CA 95616, USA

^cSchool of Food Science, Henan Institute of Science and Technology, Xinxiang, Henan 453003, China

Abstract

Glycosphingolipids are a diverse family of biologically important glycolipids. In addition to variations on the lipid component, more than 300 glycosphingolipid glycans have been characterized. These glycans are directly involved in various molecular recognition events. Several naturally occurring sialic acid forms have been found in sialic acid-containing glycosphingolipids, namely gangliosides. However, ganglioside glycans containing less common sialic acid forms are currently not available. Herein, highly effective one-pot multienzyme (OPME) systems are used in sequential for high-yield and cost-effective production of glycosphingolipid glycans, including those containing different sialic acid forms such as *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (Kdn), and 8-*O*-methyl-*N*-acetylneuraminic acid (Neu5Ac8OMe). A library of 64 structurally distinct glycosphingolipid glycans belonging to ganglio-series, lacto-/neolacto-series, and globo-/isoglobo-series glycosphingolipid glycans is constructed. These glycans are essential standards and invaluable probes for bioassays and biomedical studies.

TOC image

*Corresponding Author: hyu@glycohubusa.com, xiichen@ucdavis.edu.

†Current address: Laboratory of Bacterial Polysaccharides, Food and Drug Administration, Bethesda, MD 20892, USA

‡Current address: Center for Neuroscience, University of California, Davis, CA 95616, USA

±Current address: College of Pharmacy, Touro University, Vallejo, CA 94592, USA

Supporting Information. ¹H and ¹³C NMR spectra as well as HRMS chromatographs of synthesized glycans. This material is available free of charge via the Internet at <http://pubs.acs.org>.

Notes

HY, YL, and XC are co-founders of Glycohub, Inc., a company focused on the development of carbohydrate-based reagents, diagnostics, and therapeutics.

Keywords

carbohydrate; ganglioside; glycosphingolipid; one-pot multienzyme (OPME); oligosaccharide

1. INTRODUCTION

Glycosphingolipids are essential components of human plasma membrane. They are believed to be clustered in “lipid rafts” which are spatial mammalian cell membrane microdomains important for various biological processes including protein sorting, signal transduction, membrane trafficking, viral and bacterial infection, and cell-cell communications.¹ Aberrant expression of glycosphingolipids has been found to be associated with glycosphingolipid storage diseases and cancer progression.^{2,3} For example, increased expression of GD3 and GM2 in melanoma, elevated levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal cancers have been reported.⁴ In addition, a non-human sialic acid form, *N*-glycolylneuraminic acid (Neu5Gc), is overexpressed on several types of human tumor cells.⁵⁻⁷ Some cancer-associated gangliosides have been developed as potential cancer markers, cancer vaccine candidates,^{8,9} and immunosuppressants.¹⁰

Glycosphingolipids exhibit a large structural heterogeneity with more than 300 different glycans characterized to date. They are divided into several subfamilies including ganglio-, lacto-, neolacto-, globo-, and isoglobo-series.¹¹ The diverse glycan structures on glycosphingolipids have been found to be important for molecular recognition. Viruses and pathogenic bacteria adhesins use glycosphingolipids on the host cell surface to bind and invade epithelial cells,¹² and the binding is microbe-specific for the glycan structure.^{13,14} For example, norovirus binds ganglioside GM1, but not other glycolipids.¹² Cholera toxin also binds to GM1 on the cell surface.^{15,16} Botulinum toxin binds to GT1b and GQ1b.¹⁷ In addition, the binding of bacteria and viruses to gangliosides is specific to sialic acid forms. For example, *Escherichia coli* K99 fimbrial adhesin binds to GM3 containing Neu5Gc, but not *N*-acetylneuraminic acid (Neu5Ac).¹⁸ Neu5Gc-containing GM1 is a better ligand than Neu5Ac-containing GM1 for simian virus 40 (SV40).¹⁹ In addition to being key components in cell recognition, structurally diverse glycosphingolipids with different glycan structures are involved in cell signaling.²⁰ Therefore, obtaining pure glycosphingolipid oligosaccharides will facilitate structure- activity studies of the glycan components of glycosphingolipids at the molecular level.

Glycosphingolipids for functional studies have been traditionally purified from animal tissues by extraction.^{21,22} Heterogeneity inherited from these purification processes generates complications in data analysis and identifying the ligand that is responsible for

protein/antibody/cell-binding. Releasing glycans from glycosphingolipids purified from natural sources chemically^{21,23} or enzymatically²⁴ suffers similarly from potential contaminations. Additional challenges are limited access to the structures that are less abundant in nature and the loss of labile groups during purification and glycan cleavage processes.²⁵ Recently, significant progresses have been made on the synthesis of glycosphingolipids and their glycans. Several complex gangliosides have been synthesized by sophisticated chemical approaches.²⁶ Chemically synthesized stage-specific embryonic antigen (SSEA-3 or Gb₅) by pre-activation-based one-pot approach followed by enzymatic fucosylation and sialylation produced Globo-H and SSEA-4 (or V³Sia-Gb₅) successfully.²⁷ Globo-H has also been synthesized by total chemical synthesis,²⁸ programmable reactivity-based one-pot strategy,²⁹ and an enzymatic approach.³⁰ Chemoenzymatic synthesis of Neu5Ac-containing GD3, GT3, GM2, GD2, GT2, GM1, and GD1a ganglioside glycans with a 2-azidoethyl linker has also reported.³¹ All of these glycans obtained by chemical and enzymatic approaches either have a lipid aglycon or are tagged with a non-cleavable linker. More recently, free reducing glycans have been released from glycosphingolipids after treatment with ozone followed by heating in neutral aqueous buffer²³ but the types of the glycans produced by this method are limited as it relies on glycosphingolipids purified from natural sources. Despite the progresses in chemical and enzymatic synthesis, sialic acid-containing glycosphingolipids and the corresponding glycan head groups containing naturally occurring sialic acid forms other than the most abundant Neu5Ac are not readily available and some have never been synthesized.

Most of the earlier glycosyltransferase-catalyzed synthesis of glycosphingolipid glycans^{27,29-32} relied on the use of expensive and not readily accessible sugar nucleotides as donor substrates. Here we report the use of highly efficient sequential one-pot multienzyme (OPME) systems³³ for high-yield synthesis of complex glycosphingolipid glycans. In these systems, simple monosaccharides or derivatives can be activated by one or more enzymes to form desired sugar nucleotides for glycosyltransferase-catalyzed formation of target elongated glycans in one pot. Each OPME process adds one monosaccharide or derivative with a desired glycosidic linkage defined by the glycosyltransferase used. Multiple OPME reactions can be carried out to build up more complex glycan targets. As demonstrated here, a library of free oligosaccharides found as the glycan components of glycosphingolipids belonging to ganglio-series, lacto- and neolacto-series, as well as globo- and isoglobo-series are successfully obtained in high yields from lactose (Lac) using sequential OPME approaches (Scheme 1).

The most significant advantage of the OPME strategy is to allow easy introduction of structurally modified monosaccharides including challenging naturally occurring sialic acid forms to the desired glycan structures. As shown here, ganglioside glycans containing one or two sialic acid residues selected from four naturally occurring sialic acid forms, including *N*-acetylneuraminic acid (Neu5Ac), *N*-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-D-glycero-D-galacto-nononic acid (Kdn), and 8-*O*-methyl-*N*-acetylneuraminic acid (Neu5Ac8OMe), have been successfully obtained. The access to these structurally defined molecules will help to elucidate the important function of glycosphingolipid glycans including those containing naturally occurring sialic acid diversity which is not currently feasible.

2. RESULTS AND DISCUSSION

Chemoenzymatic synthesis of ganglioside glycans

Gangliosides are a group of sialylated glycosphingolipids that are presented in all tissues but are particularly abundant in the nervous system^{34–36} where they affect neuronal plasticity during development, adulthood, and aging.³⁷ They regulate immunological function.³⁸ Some viruses and pathogenic bacteria adhesins use gangliosides on the host cell surface for binding and invasion.¹² Lack of functional ganglioside metabolic genes leads to rare genetic disorders such as lysosomal glycosphingolipid storage diseases.³⁹ Aberrant expressing of gangliosides is associated with cancer progression.^{2,3} Therefore, some cancer-associated gangliosides have been developed as potential cancer markers, cancer vaccine candidates,^{8,9} and immunosuppressants.¹⁰ Here, four natural occurring sialic acid forms including Neu5Ac, Neu5Gc, Kdn and Neu5Ac8OMe are introduced into the structures of the target ganglioside glycans. Both Neu5Ac (in humans and animals) and Neu5Gc (in animals and small amounts in humans) are common sialic acid forms found in gangliosides.^{40,41} Kdn-containing gangliosides have been found in the sperm,⁴² ovarian fluid,⁴³ testis⁴⁴ of rainbow trouts as well as in yak milk⁴⁵ and possibly in porcine milk.⁴⁶ Neu5Ac8OMe has been found in starfish as the components of gangliosides^{47,48} and human erythrocyte membrane.⁴⁹ Its unique property of resistance to sialidases makes the glycans containing Neu5Ac8OMe moiety interesting for biofunctional studies.

Synthesis of GM3 and GD3 glycans containing Neu5Ac, Neu5Gc, Kdn, and Neu5Ac8OMe using OPME sialylation systems—Sialic acid is a key component of gangliosides. Major sialyl linkages in gangliosides are α 2–3- and α 2–8-linkages although α 2–6-sialyl linkage has also been found.⁵⁰ We have developed efficient OPME sialylation approaches for the synthesis of α 2–3/6/8-linked sialosides containing different sialic acid forms and diverse underlying glycans.^{51–53} This approach was tested and applied for the synthesis of GM3 and GD3 glycans containing different sialic acid forms including Neu5Ac, Neu5Gc, Kdn, and Neu5Ac8OMe. For the ones with Neu5Ac form, commercially available inexpensive Neu5Ac was directly used for the synthesis in one-pot two-enzyme systems containing a suitable sialyltransferase and a cytidine 5'-monophosphate sialic acid (CMP-Sia) biosynthetic enzyme *Neisseria meningitidis* CMP-sialic acid synthetase (NmCSS).⁵⁴ For the ones with other sialic acid forms including Neu5Gc, Kdn, and Neu5Ac8OMe, one-pot three-enzyme systems were used. In these systems, in addition to NmCSS and a sialyltransferase, *Pasteurella multocida* sialic acid aldolase (PmNanA) was used to form the desired sialic acid forms from their corresponding chemically synthesized precursors and pyruvate.

As shown in Scheme 2, GM3 trisaccharide containing Neu5Ac (Neu5Ac α 2–3Lac, **1**) was readily synthesized in an excellent 98% yield from lactose as the acceptor substrate and Neu5Ac as the donor precursor using a one-pot two-enzyme system (OPME1) containing NmCSS and *Pasteurella multocida* α 2–3-sialyltransferase 1 M144D mutant (PmST1 M144D)⁵⁵ with decreased α 2–3-sialidase and donor hydrolysis activity. On the other hand, GM3 trisaccharides containing Neu5Gc, Kdn, and Neu5Ac8OMe (Neu5Gc α 2–3Lac, **2**; Kdn α 2–3Lac, **3**; and Neu5Ac8OMe α 2–3Lac, **4**) were synthesized from lactose and the

corresponding sialic acid precursors *N*-glycolylmannosamine (ManNGc), mannose (Man), and 5-*O*-methyl-*N*-acetylmannosamine (ManNAc5OMe),⁵⁶ respectively, in excellent yields (93%, 95%, and 91%, respectively) using a one-pot three-enzyme system (OPME2) containing PmNanA, NmCSS, and PmST1 M144D.

Three synthetic GM3 trisaccharides Neu5Ac/Neu5Gc/Kdn α 2-3Lac (**1–3**) were further used as acceptor substrates for synthesizing nine GD3 tetrasaccharides using a *Campylobacter jejuni* α 2-3/8-sialyltransferase (CjCstII)⁵²-dependent one-pot two-enzyme (OPME3 when Neu5Ac was used as the sialyltransferase donor precursor) or a one-pot three-enzyme (OPME4 when ManNGc or Man was used as the sialic acid precursor) α 2-8-sialylation system. From Neu5Ac α 2-3Lac (**1**), OPME3 and OPME4 produced three GD3 glycans Neu5Ac α 2-8Neu5Ac α 2-3Lac (**5**), Neu5Gc α 2-8Neu5Ac α 2-3Lac (**6**), and Kdn α 2-8Neu5Ac α 2-3Lac (**7**) in good 85%, 84%, and 83% yields, respectively. Similarly, from Neu5Gc α 2-3Lac (**2**), three GD3 glycans Neu5Ac α 2-8Neu5Gc α 2-3Lac (**8**), Neu5Gc α 2-8Neu5Ac α 2-3Lac (**9**), and Kdn α 2-8Neu5Ac α 2-3Lac (**10**) were synthesized in good 86%, 83%, and 81% yields, respectively. From Kdn α 2-3Lac (**3**), three GD3 glycans Neu5Ac α 2-Kdn α 2-3Lac (**11**), Neu5Gc α 2-Kdn α 2-3Lac (**12**), and Kdn α 2-Kdn α 2-3Lac (**13**), were synthesized in 82%, 78%, 81% yields, respectively. Neu5Ac8OMe α 2-3Lac (**4**) has a *O*-methyl group at C-8 of the terminal sialic acid and cannot be used for adding an additional α 2-8-linked sialic acid. In addition, CMP-Neu5Ac8OMe (formed *in situ* in the OPME4 system) was found as a poor donor substrate for CjCstII. Therefore, the corresponding GD3 glycan containing a terminal Neu5Ac8OMe was not produced.

Synthesis of GM2 and GD2 glycans using an OPME β 1-4-GalNAc transfer system—

The synthesis of GM2 and GD2 glycans involved the use of *Campylobacter jejuni* β 1-4GalNAcT (CjCgtA). The gene sequence of this enzyme was reported before.⁵⁷ A recombinant CjCgtA was used previously for the synthesis of ganglioside oligosaccharides containing an ethyl azido aglycon.³¹ In our attempts to obtain an active CjCgtA and improve its expression level, a customer synthesized synthetic gene based on the *Campylobacter jejuni* CgtA-II protein sequence (GenBank accession number: AAL05993) was used as a template for polymerase-chain reaction (PCR) for cloning into pET22b(+) vector. In addition, series truncation of N-terminal sequence was carried out. Compared to the full length construct and the constructs with N-terminal 10 amino acid (aa), 20 aa, or 25 aa truncation, the one with the N-terminal 15 aa had a higher expression level (40 mg/L culture). Therefore, it was expressed and used for synthesis. The purified CjCgtA samples were not stable for storage at 4 °C. In comparison, purified CjCgtA and lysates could be stored at -20 °C for over a year without significant loss of activity. CjCgtA lysate was used directly in the enzymatic synthesis.

As shown in Scheme 3, four GM2 tetrasaccharides Neu5Ac α 2-3(GalNAc β 1-4)Lac (**14**), Neu5Gc α 2-3(GalNAc β 1-4)Lac (**15**), Kdn α 2-3(GalNAc β 1-4)Lac (**16**), and Neu5Ac8OMe α 2-3(GalNAc β 1-4)Lac (**17**) were readily obtained from four synthetic GM3 (**1–4**) trisaccharides in extremely high yields (95–99%) using an OPME β 1-4-GalNAc activation and transfer system (OPME5) containing CjCgtA and uridine 5'-diphosphate *N*-acetylgalactosamine (UDP-GalNAc) biosynthetic enzymes including *Bifidobacterium*

longum *N*-acetylhexosamine-1-kinase (BLNahK, NahK_ATCC55813), *Pasteurella multocida* *N*-acetylglucosamine uridylyltransferase (PmGlmU), *Pasteurella multocida* inorganic pyrophosphatase (PmPpA). All four enzymes were quite active in Tris-HCl buffer at pH 7.5.

The same OPME5 system (Scheme 3) was also used for the synthesis of eight GD2 pentasaccharides (**18–25**) from GD3 tetrasaccharides (**5–10**, **12–13**). Neu5Aca2–8Neu5Aca2–3(GalNAc β 1–4)Lac (**18**), Neu5Gca2–8Neu5Aca2–3(GalNAc β 1–4)Lac (**19**), Kdna2–8Neu5Aca2–3(GalNAc β 1–4)Lac (**20**), Neu5Aca2–8Neu5Gca2–3(GalNAc β 1–4)Lac (**21**), Neu5Gca2–8Neu5Gca2–3(GalNAc β 1–4)Lac (**22**), Kdna2–8Neu5Gca2–3(GalNAc β 1–4)Lac (**23**), Neu5Gca2–8Kdna2–3(GalNAc β 1–4)Lac (**24**), and Kdna2–8Kdna2–3(GalNAc β 1–4)Lac (**25**), were obtained in excellent yields (nearly quantitative conversion).

Synthesis of GM1 and GD1b glycans using an OPME β 1–3-galactosylation system—As shown in Scheme 3, the synthesis of GM1 pentasaccharides (**26–29**) from GM2 tetrasaccharides (**14–17**) was achieved using a one-pot four-enzyme galactose-activation and transfer system (OPME6) containing *Campylobacter jejuni* β 1–3-galactosyltransferase (CjCgtB) and uridine 5'-diphosphate galactose (UDP-Gal) biosynthetic enzymes including *Escherichia coli* galactokinase (EcGalK),⁵⁸ *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP), and PmPpA. GD1b hexasaccharides (**30–34**) containing different sialic acid forms from the corresponding GD2 pentasaccharides (**18**, **19**, **22**, **23**, and **25**) were synthesized similarly. Excellent yields were achieved using 1.1 equivalent of galactose (Gal) as the donor precursor by incubating reaction mixtures in Tris-HCl (100 mM, pH 7.5) at 37 °C for 24 hours. It was found important not to add larger equivalents of Gal. Otherwise, an additional Gal would be added to the desired GM1 and GD1b products.

Synthesis of lacto- and neolacto-series glycosphingolipid glycans

Lacto- and neolacto-series glycosphingolipids differ only by one galactosyl linkage: Gal β 1–3Lc₃ for Lc₄ in the lacto-series and Gal β 1–4Lc₃ for nLc₄ in the neolacto-series. Lc₄ is a precursor for fucosyltransferase-catalyzed formation of Le^a and Le^b. Taking advantage of PmST1 M144D which was shown previously to be able to tolerate fucosylated acceptors with or without further *O*-sulfation,⁵⁹ direct α 2–3-sialylation of Le^a can form sialyl Le^a (sLe^a). While nLc₄ is a precursor for fucosyltransferase-catalyzed formation of Le^x and Le^y, and α 2–3-sialylation of Le^x using PmST1 M144D can form sialyl Le^x (sLe^x). Neolacto-series glycosphingolipids have been found on the surface of human hematopoietic cells and are involved in the differentiation of hematopoietic cells.⁶⁰ Le^a, sLe^a, Le^x, and sLe^x have been found to be overexpressed on some cancer cell surface.^{61–63}

As shown in Scheme 4, LNnT Gal β 1–4GlcNAc β 1–3Lac (**36**) was synthesized from lactose using a sequential two-step OPME³³ process similar to that was reported previously.⁶⁴ Briefly, Lc₃ trisaccharide GlcNAc β 1–3Lac **35** was synthesized from lactose (Lac) and *N*-acetylglucosamine (GlcNAc) in a 94% yield using a one-pot four-enzyme GlcNAc activation and transfer system (OPME7) containing *Neisseria meningitidis* β 1–3-*N*-

acetylglucosaminyltransferase (NmLgtA) and uridine 5'-diphosphate *N*-acetylglucosamine (UDP-GlcNAc) biosynthetic enzymes (the same set of enzymes for UDP-GalNAc biosynthesis in OPME5) including BLNahK (NahK_ATCC55813), PmGlmU, PmPpA. Lacto-*N*-neotetraose (LNnT) tetrasaccharide Gal β 1-4GlcNAc β 1-3Gal β 1-4Glc **36** was then synthesized from Lc₃ (**35**) and galactose in an excellent (99%) yield using a OPME galactose activation and transfer system (OPME8)⁶⁴ containing *Neisseria meningitidis* β 1-4-galactosyltransferase (NmLgtB) and UDP-Gal biosynthetic enzyme including EcGalK, BLUSP, and PmPpA (the same set of UDP-Gal biosynthetic enzymes in OPME6).

With LNnT in hand, sialylated LNnT pentasaccharides containing Neu5Ac, Neu5Gc, Kdn, and Neu5Ac8OMe (**37–40**) were successfully synthesized using OPME1 sialylation system with Neu5Ac as the donor precursor or OPME2 sialylation system with ManNGc, Man, or ManNAc5OMe as the sialic acid precursor.

Similarly, sialylated lacto-*N*-tetraose (LNT) pentasaccharides containing Neu5Ac, Neu5Gc, Kdn, and Neu5Ac8OMe (**42–45**) were obtained via OPME1 or OPME2 sialylation system using commercial available LNT (**41**) as the acceptor substrate and Neu5Ac, ManNGc, Man, and ManNAc5OMe, respectively, as donor precursors (Scheme 5).

Although sialylated Le^x pentasaccharides **47–50** can be synthesized by fucosylation of sialylated LNnT **37–40**, purification of the product from starting materials in these fucosylation reactions was found difficult due to their similarity in sizes and polarity. To simplify the production and purification processes, fucosylated LNnT **46** was synthesized and used as the acceptor substrate for PmST1 M144D-catalyzed OPME α 2-3-sialylation. This was made feasible by a single mutation M144D introduced to PmST1 which made the α 2-3-sialylation of fucosylated acceptors efficient by reducing donor hydrolysis and α 2-3-sialidase activity of PmST1.⁵⁹ As shown in Scheme 6, Le^x pentasaccharide Gal β 1-4(Fuc α 1-3)GlcNAc β 1-3Lac (**46**) was synthesized in a preparative-scale (500 mg) in an excellent 94% yield from LNnT tetrasaccharide (**36**), using a one-pot three-enzyme fucose activation and transfer system (OPME9) containing *Helicobacter pylori* α 1-3-fucosyltransferase (Hp1-3FT)⁵⁵ and guanosine 5'-diphosphate fucose (GDP-Fuc) biosynthetic enzymes including a bifunctional *Bacteroides fragilis* L-fucokinase and guanidine 5'-diphosphate (GDP)-fucose pyrophosphorylase (BfFKP)⁶⁵ and PmPpA. Sialylated Le^x pentasaccharides **47–50** were then synthesized from **46** via OPME1 or OPME2 sialylation system with Neu5Ac, ManNGc, Man, or ManNAc5OMe as the sialyltransferase donor precursor.

Synthesis of globo- and isoglobo-glycosphingolipid glycans

The globo (Gb) and isoglobo (iGb) series glycosphingolipid glycans are built, respectively, on trisaccharides Gb₃ (Gal α 1-4Lac) and iGb₃ (Gal α 1-3Lac) that differ by only one terminal Gal linkage. Globo-series glycosphingolipids are used as receptors by Shiga toxin,⁶⁶ verotoxins, and HIV adhesin gp120.⁶⁷ They have also attracted much attentions due to their overexpression in cancer⁶⁸ and accumulation in Fabry's disease.⁶⁹ Tumor-associated Globo H antigen was initially identified from human breast cancer cell line MCF-7⁷⁰ and

was later found in several human cancers. Globo H-based synthetic vaccines have shown promising results in clinical trials for breast and prostate cancers.⁷¹⁻⁷⁴

As shown in Scheme 7, Gb₃ trisaccharide Gal α 1-4Lac (**51**) was readily obtained in an excellent 95% yield from Lac, Gal, adenosine 5'-triphosphate (ATP), and uridine 5'-triphosphate (UTP) using an OPME α 1-4-galactosylation system (OPME10) containing *N. meningitidis* α 1-4-galactosyltransferase (NmLgtC)^{75,76} and UDP-Gal biosynthetic enzymes including EcGalK, BLUSP, and PmPpA. On the other hand, iGb₃ trisaccharide Gal α 1-3Lac (**52**) was synthesized in an outstanding 99% yield from Lac, Gal, ATP, and UTP using an OPME α 1-3-galactosylation system (OPME11) containing a recombinant bovine α 1-3GalT (Ba1-3GalT)⁷⁷ and UDP-Gal biosynthetic enzymes including EcGalK, BLUSP, and PmPpA.

A bifunctional *Haemophilus influenzae* β 1-3GalT/ β 1-3GalNAcT (HiLgtD)^{78,79} was used to catalyze the transfer of GalNAc from *in situ* generated UDP-GalNAc to Gb₃ (**51**) and iGb₃ (**52**) in an OPME β 1-3-GalNAc transfer system (OPME12) containing HiLgtD and UDP-GalNAc biosynthetic enzymes NahK, PmGlmU, and PmPpA to produce Gb₄ (**53**, 92%) and iGb₄ (**54**, 91%) tetrasaccharides, respectively, in excellent yields.

For the synthesis of Gb₅ (**55**) and iGb₅ (**56**) pentasaccharides by adding a β 1-3-linked Gal to Gb₄ (**53**) and iGb₄ (**54**) tetrasaccharides, respectively, the bifunctional HiLgtD (having both β 1-3-Gal and β 1-3-GalNAc transferase activities) was initially tested. However, it was found that HiLgtD-catalyzed reaction for forming pentasaccharides was very low. In comparison, CjCgtB was found to be able to catalyze the transfer of Gal from UDP-Gal to Gb₄ to form Gb₅ in moderate yields. Therefore, Gb₅ (**55**) and iGb₅ (**56**) pentasaccharides were synthesized from Gb₄ (**53**) and iGb₄ (**54**) tetrasaccharides using CjCgtB-containing OPME6 in 61% and 45% yields, respectively.

Gb₅ (**55**) and iGb₅ (**56**) pentasaccharides were then used as the acceptor substrates in PmST1 M144D-containing OPME α 2-3-sialylation (OPME1 or OPME2) systems to produce sialylated Gb₅ (**57-60**, 78-86%) and sialylated iGb₅ (**61-64**, 71-85%) hexasaccharides containing Neu5Ac, Neu5Gc, Kdn, and Neu5Ac8OMe sialic acid forms, respectively, with good yields.

Enzymatic reaction conditions and purification processes

A pH range of 8.0-8.5 was found to be optimal and Tris-HCl buffer (100 mM, pH 8.5) was used in the OPME sialylation systems for the synthesis of desired sialosides. In comparison, a pH range of 7.5-8.0 was found to be more suitable and Tris-HCl buffer (100 mM, pH 8.0) was used in NmLgtB-containing OPME reaction for the synthesis of LNnT (**36**). On the other hand, Tris-HCl buffer (100 mM, pH 7.5) was used in CjCgtA-containing OPME GalNAc-transfer system for the production of GM2 and GD2, NmLgtA-catalyzed GlcNAc-transfer system for the synthesis of Lc₃ (GlcNAc β 1-3Lac), and other OPME galactosylation (including CjCgtB-catalyzed production of GM1, GD1b, Gb₅, and iGb₅, Ba1-3GalT/NmLgtC/HiLgtD-catalyzed OPME galactosylation for the production of Gb₃, iGb₃, Gb₄, and iGb₄). OPME fucosylation of LNnT was also carried out at Tris-HCl buffer (100 mM, pH 7.5). Reactions were carried out at 37 °C or at room temperature and were completed in

a time frame of 2–48 h. The reaction progress was monitored by thin-layer chromatography (TLC) and mass spectrometry (MS).

The combinations of various columns were used to purify target glycans from OPME reactions. A simple silica gel column followed by a final gel filtration column packed with Bio-gel P2 resin were used to purify Gb₃, iGb₃, Gb₄, and iGb₄ glycans (**51–54**). For purifying GM3 trisaccharides (**1–4**), Lc₃ trisaccharide (**35**), nLc₄ tetrasaccharide (**36**), and Le^x pentasaccharide (**46**), a Bio-gel P2 gel filtration column followed by a silica gel column and a final gel filtration column for desalting were used. For purifying sialylated LNnT, LNT, Le^x (**37–50**) as well as Gb₅ (**55**), iGb₅ (**56**), and their sialylated glycans (**57–64**), Bio-gel P2 gel filtration column followed by high-performance liquid chromatography (HPLC) purification with a reverse-phase C18 column was used. For purifying GD3 tetrasaccharides (**5–13**), sialyl Le^x hexasaccharides (**47–50**), Bio-gel P2 gel filtration column followed by silica gel column and HPLC purification with a reverse-phase C18 column was used. For purifying GM2 tetrasaccharides (**14–17**), GD2 pentasaccharides (**18–25**), GM1 pentasaccharides (**26–29**), and GD1 hexasaccharides (**30–34**), Bio-gel P2 gel filtration column followed by HPLC purification using an XBridge BEH amide column was used. We have also found that the addition of a commercially available alkaline phosphatase from bovine intestinal mucosa to reaction mixture after glycosylation reactions could efficiently break down nucleotide byproducts (e.g. ADP, AMP, UDP, UMP, and GDP) byproducts and make the purification procedures much easier.

3. CONCLUSIONS

In conclusion, we have successfully applied sequential one-pot multienzyme (OPME) systems for high-yield and cost-effective production of glycosphingolipid glycans including those belonging to the ganglio-, lacto-, neolacto-, globo-, and isoglobo-series. The OPME approaches allow easy introduction of naturally occurring structurally modified diverse sialic acid forms to glycosphingolipid glycans. These glycans are essential standards for glycan analysis and critical probes for bioassays and biomedical studies for developing novel carbohydrate-based diagnostics and therapeutics.

4. EXPERIMENTAL SECTION

Materials and general methods

All reagents were purchased from commercial sources and used without further purification unless stated otherwise. ¹H and ¹³C spectra were measured in the solvent stated at 800 MHz, and 200 MHz, respectively. Chemical shifts are quoted in parts per million (ppm) and coupling constants (J) are given in Hertz (Hz). Multiplicities are abbreviated as br (broad), s (singlet), d (doublet), t (triplet), q (quartet), and m (multiplet) or combinations thereof. High resonance mass spectrometry samples were analyzed by electrospray ionization mass spectrometry in positive mode or negative mode using flow-injection analysis. Glass-backed TLC plates (Silica Gel 60 with a 254 nm fluorescent indicator) were used without further manipulation. Developed TLC plates were visualized with anisaldehyde sugar stain and heat provided by a hotplate. Silica gel flash column chromatography was performed using flash silica gel (40–63 μm) and employed a solvent polarity correlated with TLC mobility. Gel

filtration chromatography was performed with a column (100 cm × 2.5 cm) packed with BioGel P-2 Fine resins.

Cloning of CjCgtA-His₆—Synthetic DNA based on *Campylobacter jejuni* CgtA-II protein sequence (GenBank accession number: AAL05993) and optimized for *Escherichia coli* was customer synthesized by Biomatik. It was used as a template for target gene amplification of the full-length and N-terminal truncated constructs by polymerase chain reactions (PCRs) for cloning into pET22b(+) vector. The primers used were reverse 5′-CAGCGTCGACTTTGATCTCACCTGAACTTC TTCAG-3′ (*Sa*I restriction site is underlined); full length CgtA-His₆ forward 5′-GATCCATATGCTGAAAAAGATTATCAGCCTGT ACAAG-3′ (*Nde*I restriction site is underlined); 10CgtA-His₆ forward 5′-GATCCATATGCGCTACAGCATCAGCAAGAAAC TGGTG-3′ (*Nde*I restriction site is underlined); 15CgtA-His₆ forward 5′-GATCCATATGAAGAACTGGTGCTGGACAAC GAGCAC-3′ (*Nde*I restriction site is underlined); 20CgtA-His₆ forward 5′-GATCCATATGGACAACGAGCACTTTATTAAGG-3′ (*Nde*I restriction site is underlined). PCRs for amplifying the target gene were each performed in a 50 μL reaction mixture containing plasmid DNA (10 ng), forward and reverse primers (0.2 μM each), 1 × Herculanase buffer, dNTP mixture (0.2 mM), and 5 U (1 μL) of Herculanase-enhanced DNA polymerase. The reaction mixture was subjected to 30 cycles of amplification at an annealing temperature of 55°C. The resulted PCR product was purified and double digested with *Nde*I and *Sa*I restriction enzymes. The purified and digested PCR product was ligated with the predigested pET22b(+) vector and transformed into *E. coli* DH5α electrocompetent cells. Selected clones were grown for minipreps and characterized by restriction mapping. Positive construct was transformed into *E. coli* BL21 (DE3) chemical component cells.

Expression and purification of enzymes involved in the synthesis—This was carried out similarly to those reported previously.^{54,55,80} Briefly, *E. coli* BL21 (DE3) strains harboring the recombinant plasmid with target gene was cultured in 50 mL Luria-Bertani (LB) rich medium (10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl) containing 0.1 mg/mL ampicillin with rapid shaking (220 rpm) at 37 °C overnight. Then 15 mL of the overnight cell culture was transferred into 1 L of LB rich medium with 0.1 mg/mL ampicillin and incubated at 37 °C. When the OD_{600nm} of the cell culture reached 0.8–1.0, isopropyl-1-thio-β-D-galactopyranoside (IPTG, 0.1 mM) was added to induce the over-expression of the recombinant enzyme, which was followed by incubation at 20 °C with shaking (190–250 rpm) for 20 h. Cells were collected by centrifugation at 4000 rpm for 2 h at 4 °C. Harvested cells were resuspended with lysis buffer (100 mM Tris-HCl buffer, pH 8.0, containing 0.1% Triton X-100). The cells were broken by sonication to obtain cell lysate which was centrifuged at 12,000 rpm for 15 min at 4 °C. The supernatant was collected and loaded onto a Ni²⁺-NTA affinity column pre-equilibrated with a binding buffer (50 mM, pH 7.5, Tris-HCl buffer, 5 mM imidazole, 0.5 M NaCl). The column was washed with 10 column volumes of binding buffer and 10 column volumes of washing buffer (50 mM Tris-HCl buffer, pH 7.5, 20 mM imidazole, 0.5 M NaCl). The target protein was eluted using Tris-HCl buffer (50 mM, pH 7.5) containing 200 mM of imidazole and NaCl (0.5 M).

General procedures for OPME synthesis of GM3 glycans (4 compounds)—Lac (20 mM, 1 eq.), Neu5Ac or a sialic acid precursor (ManNGc, mannose, or ManNAc5OMe, 1.5 eq.) with sodium pyruvate (7.5 eq.) were incubated at 37 °C in a Tris-HCl buffer (100 mM, pH 8.5) containing CTP (1.5 eq.), MgCl₂ (20 mM), NmCSS (0.15 mg/mL), PmST1 M144D (0.3 mg/mL), with or without PmNanA (0.2 mg/mL, omit if Neu5Ac was used). The reaction was monitored by TLC with a developing reagent constituted of *i*-PrOH:H₂O:NH₄OH= 5:2:1 (by volume) and stained with *p*-anisaldehyde sugar Reactions were typically completed in 12–24 h. Upon completion, to the reaction mixture was added the same volume of ethanol and incubated at 4 °C for 30 min before the mixture was centrifuged to remove precipitates. The supernatant was concentrated and passed through a BioGel P-2 gel filtration column and eluted with degassed water. The fractions containing the product were collected, concentrated, and further purified by silica gel column (EtOAc:MeOH:H₂O, 4:2:1). The collected fractions were concentrated and passed through the gel filtration column again to obtain the desired GM3 glycans (yield from 91% to 98%).

Neu5Acα2–3Lac (1): 2.1 g, yield 98%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.21 (d, *J* = 4.0 Hz, 0.4H), 4.65 (d, *J* = 8.0 Hz, 0.6H), 4.52 (d, *J* = 8.0 Hz, 1H), 4.11–3.26 (m, 19H), 2.74 (dd, *J* = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 1.79 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 174.87, 173.77, 102.49, 99.66, 95.65, 91.70, 78.15, 78.01, 75.35, 75.05, 74.68, 74.20, 73.67, 72.74, 71.65, 71.26, 71.02, 69.97, 69.24, 68.24, 67.96, 67.33, 62.44, 60.91, 59.93, 59.78, 51.55, 39.51, 21.92. HRMS (ESI) *m/z* calcd for C₂₃H₃₈NO₁₉ (M-H) 632.2038, found 632.2036. NMR data were consistent with those reported in the literature.⁵³

Neu5Gcaα2–3Lac (2): 360 mg, yield 93%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.21 (d, *J* = 4.0 Hz, 0.4H), 4.64 (d, *J* = 8.0 Hz, 0.6H), 4.51 (d, *J* = 8.0 Hz, 1H), 4.10 (s, 2H), 4.10–3.26 (m, 19H), 2.75 (dd, *J* = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 1.80 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 175.65, 173.82, 102.51, 102.49, 99.68, 95.63, 91.72, 78.16, 78.01, 75.34, 75.05, 74.68, 74.20, 73.70, 73.66, 72.46, 71.74, 71.67, 71.02, 69.26, 69.24, 68.00, 67.96, 67.88, 67.37, 67.31, 62.44, 62.38, 60.94, 60.92, 60.86, 59.94, 59.80, 59.19, 51.29, 51.22, 39.58, 39.55; HRMS (ESI) *m/z* calcd for C₂₃H₃₈NO₂₀ (M-H) 648.1987, found 648.1984. NMR data were consistent with those reported in the literature.⁸¹

Kdnaα2–3Lac (3): 82 mg, yield 95%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.19 (d, *J* = 4.0 Hz, 0.3H), 4.63 (d, *J* = 8.0 Hz, 0.7H), 4.50 (d, *J* = 8.0 Hz, 1H), 4.07–3.24 (m, 19H), 2.67 (dd, *J* = 12.0 and 4.8 Hz, 1H), 1.72 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 173.93, 170.45, 102.50, 99.65, 95.65, 91.69, 78.13, 77.99, 75.32, 75.05, 74.68, 74.20, 73.78, 73.68, 71.95, 71.25, 71.02, 70.12, 69.97, 69.61, 69.23, 67.58, 67.28, 62.49, 60.91, 59.93, 59.79, 39.16; HRMS (ESI) *m/z* calcd for C₂₁H₃₅O₁₉ (M-H) 591.1773, found 591.1782. NMR data were consistent with those reported in the literature.⁵³

Neu5Ac8OMeα2–3Lac (4): 12 mg, yield 91%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.21 (d, *J* = 3.2 Hz, 0.4H), 4.66 (d, *J* = 8.0 Hz, 0.6H), 4.49 (d, *J* = 8.0 Hz, 1H), 4.08–3.26 (m, 19H), 3.48 (s, 3H), 2.67 (dd, *J* = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 1.75 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 174.84, 173.54, 102.65, 100.09, 95.66, 91.72, 80.20, 78.17, 78.02, 75.64, 75.12, 74.73, 74.17, 73.70, 72.71, 71.23, 71.05, 70.02, 69.27, 67.91,

67.59, 66.86, 60.92, 59.94, 59.80, 59.23, 57.40, 51.89, 39.70, 21.96; HRMS (ESI) m/z calcd for $C_{24}H_{40}NO_{19}$ (M-H) 646.2195, found 646.2191.

General procedures for OPME synthesis of GD3 glycans (9 compounds)—A GM3 glycan (20 mM, 1 eq.) as an acceptor for the α 2–8-sialyltransferase activity of CjCstII, Neu5Ac or a sialic acid precursor (ManNGc, mannose, or ManNAc5OMe, 1.2 eq.) with sodium pyruvate (7.5 eq.) were incubated at 37 °C in Tris-HCl buffer (100 mM, pH 8.5), CTP (1.5 eq.), $MgCl_2$ (20 mM), NmCSS (0.15 mg/mL), CjCstII (0.35 mg/mL) with or without PmNanA (0.2 mg/mL, omit if Neu5Ac was used). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for 2 h (or at room temperature for overnight) with agitation at 140 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, the reaction was quenched by adding the same volume of ice-cold ethanol and incubation at 4 °C for 30 min. The mixture was centrifuged and the precipitates were removed. The supernatant was concentrated, passed through a BioGel P-2 gel filtration column and eluted with water to obtain sialoside mixtures. The fractions containing the product were collected and then purified by silica gel column (EtOAc:MeOH:H₂O, 5:3:2). The compound was further purified by a reverse-phase C18 column (10 μ m, 21.2 $\times$ 250 mm) with a flow rate of 10 mL/min using a gradient elution of 0–100% acetonitrile in water containing 0.05% formic acid over 20 minutes [Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: acetonitrile (v/v); Gradient: 0% B for 3 minutes, 0% to 100% B over 12 minutes, 100% B for 2 minutes, then 100% to 0% B over 3 minutes]. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing the pure product were collected and concentrated to obtain the final pure GD3 glycans (yields 78–86%).

Neu5Aca2–8Neu5Aca2–3Lac (5): 1.4 g, yield 86%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.21 (d, J = 3.2 Hz, 0.4H), 4.66 (d, J = 8.0 Hz, 0.6H), 4.52 (d, J = 7.2 Hz, 1H), 4.16–4.07 (m, 3H), 3.99–3.25 (m, 23H), 2.77 (dd, J = 4.8 and 12.8 Hz, 1H), 2.67 (dd, J = 4.8 and 12.8 Hz, 1H), 2.06 (s, 3H), 2.02 (s, 3H), 1.73 (t, J = 12.0 Hz, 2H). ¹³C NMR (200 MHz, D₂O) δ 174.88, 174.86, 174.81, 173.39, 173.24, 102.57, 102.54, 100.41, 100.08, 100.07, 95.70, 95.66, 91.75, 91.70, 78.08, 77.97, 77.83, 75.33, 75.10, 74.71, 74.14, 73.89, 73.76, 73.71, 72.53, 71.69, 71.59, 71.24, 71.07, 70.06, 69.25, 69.18, 69.16, 68.36, 68.27, 68.02, 67.99, 67.80, 67.39, 67.30, 62.41, 61.49, 61.46, 61.43, 60.99, 59.96, 59.89, 59.81, 59.74, 52.24, 52.18, 52.15, 52.10, 51.66, 51.63, 51.58, 40.39, 40.35, 39.62, 39.53, 22.23, 21.96. HRMS (ESI) m/z calculated for $C_{34}H_{55}N_2O_{27}$ (M-H) 923.2992, found 923.2983. NMR data were consistent with those reported in the literature.⁵²

Neu5Gca2–8Neu5Aca2–3Lac (6): 52 mg, yield 84%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.16 (m, 1H), 4.12 (m, 1H), 4.10 (s, 2H), 4.10 (s, 2H), 4.06 (m, 1H), 3.97–3.25 (m, 23H), 2.77 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 1.73 (t, J = 12.0 Hz, 1H), 1.723 (t, J = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 175.61, 174.85, 173.37, 173.26, 102.55, 102.53, 100.38, 100.05, 100.03, 95.67, 91.71, 78.10, 77.94, 77.78, 75.33, 75.10, 74.71, 74.14, 73.89, 73.71, 72.24, 71.68, 71.20, 71.06, 70.00, 69.16, 68.11,

67.91, 67.80, 67.32, 62.38, 61.44, 60.99, 60.84, 59.86, 52.14, 51.31, 40.42, 39.57, 22.19. HRMS (ESI) m/z calculated for $C_{34}H_{55}N_2O_{28}$ (M-H) 939.2941, found 939.2920.

Kdna2-8Neu5Aca2-3Lac (7): 39 mg, yield 83%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.51 (d, J = 8.0 Hz, 0.4H), 4.50 (d, J = 8.0 Hz, 0.6H), 4.16–4.06 (m, 3H), 3.97–3.26 (m, 23H), 2.70 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 1.72 (t, J = 12.0 Hz, 1H), 1.69 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.85, 173.45, 173.36, 143.29, 102.54, 100.90, 100.37, 100.06, 95.66, 91.71, 78.02, 77.96, 77.80, 75.33, 75.10, 74.70, 74.14, 73.88, 73.70, 73.52, 71.91, 71.20, 71.06, 70.27, 70.00, 69.69, 69.19, 69.15, 67.80, 67.63, 67.33, 62.49, 61.42, 60.98, 59.87, 59.72, 59.29, 52.14, 39.92, 39.55, 22.19. HRMS (ESI) m/z calculated for $C_{32}H_{52}NO_{27}$ (M-H) 882.2727, found 882.2719.

Neu5Aca2-8Neu5Gca2-3Lac (8): 121 mg, yield 86%; white solid. 1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.3H), 4.63 (d, J = 8.0 Hz, 0.7H), 4.49 (d, J = 8.0 Hz, 1H), 4.17–3.24 (m, 28H), 2.73 (dd, J = 4.8 and 12.8 Hz, 1H), 2.67 (dd, J = 4.8 and 12.8 Hz, 1H), 1.99 (s, 3H), 1.71 (t, J = 12.0 Hz, 2H). ^{13}C NMR (200 MHz, D_2O) δ 175.94, 174.86, 174.84, 174.60, 173.50, 173.29, 172.49, 170.61, 170.59, 102.60, 102.52, 101.94, 100.11, 100.04, 95.68, 95.65, 78.28, 75.37, 75.32, 75.08, 74.69, 74.12, 73.77, 73.69, 73.59, 72.68, 72.49, 71.77, 71.60, 71.06, 69.16, 68.98, 68.91, 68.28, 68.22, 67.98, 67.82, 67.46, 67.28, 62.50, 61.34, 61.30, 60.98, 59.18, 52.01, 51.88, 51.65, 40.42, 39.51, 39.10, 21.95, 21.91. HRMS (ESI) m/z calculated for $C_{34}H_{55}N_2O_{28}$ (M-H) 939.2941, found 939.2935.

Neu5Gca2-8Neu5Gca2-3Lac (9): 76 mg, yield 83%; white solid. 1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.18 (d, J = 16.8 Hz, 1H), 4.16 (m, 1H), 4.13 (m, 1H), 4.10 (s, 2H), 4.09 (d, J = 16.8 Hz, 1H), 4.07 (m, 1H), 3.98–3.25 (m, 23H), 2.76 (dd, J = 12.0 and 4.8 Hz, 1H), 2.68 (dd, J = 12.0 and 4.8 Hz, 1H), 1.73 (t, J = 12.0 Hz, 2H); ^{13}C NMR (200 MHz, D_2O) δ 175.61, 174.85, 173.37, 173.26, 102.55, 102.53, 100.38, 100.05, 100.03, 95.67, 91.71, 78.10, 77.94, 77.78, 75.33, 75.10, 74.71, 74.14, 73.89, 73.71, 72.24, 71.68, 71.20, 71.06, 70.00, 69.16, 68.11, 67.91, 67.80, 67.32, 62.38, 61.44, 60.99, 60.84, 59.86, 52.14, 51.31, 40.42, 39.57, 22.19. HRMS (ESI) m/z calculated for $C_{34}H_{55}N_2O_{29}$ (M-H) 955.2890, found 955.2900.

Kdna2-8Neu5Gca2-3Lac (10): 62 mg, yield 81%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.18 (d, J = 16.8 Hz, 1H), 4.15 (m, 1H), 4.12 (m, 1H), 4.08 (d, J = 16.8 Hz, 1H), 4.07 (m, 1H), 3.97–3.26 (m, 23H), 2.68 (m, 2H), 1.73 (t, J = 12.0 Hz, 1H), 1.67 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 176.06, 173.83, 173.38, 102.66, 100.10, 95.74, 91.79, 78.36, 78.04, 77.89, 75.45, 75.21, 74.79, 74.21, 73.79, 73.69, 73.58, 72.02, 71.27, 71.14, 70.27, 70.09, 69.76, 69.23, 69.01, 67.74, 67.41, 62.59, 61.42, 61.08, 59.97, 59.82, 52.06, 48.64, 40.16, 39.70. HRMS (ESI) m/z calculated for $C_{32}H_{52}NO_{28}$ (M-H) 898.2676, found 898.2668.

Neu5Aca2-8Kdna2-3Lac (11): 24 mg, yield 82%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J

= 8.0 Hz, 0.6H), 4.18–3.25 (m, 26H), 2.76–2.61 (m, 2H), 2.01 (s, 3H), 1.80–1.70 (m, 2H); ^{13}C NMR (200 MHz, D_2O) δ 174.83, 169.88, 102.54, 95.66, 91.71, 77.93, 77.83, 77.69, 75.38, 75.10, 74.90, 74.71, 74.15, 73.71, 73.54, 72.60, 71.59, 71.20, 71.06, 70.59, 70.40, 70.00, 69.46, 69.35, 69.17, 69.13, 68.77, 68.37, 68.31, 68.04, 67.86, 67.47, 67.38, 67.32, 62.46, 61.23, 61.03, 60.97, 59.90, 52.20, 51.60, 40.35, 39.78, 39.05, 22.19, 22.09. HRMS (ESI) m/z calculated for $\text{C}_{32}\text{H}_{52}\text{NO}_{27}$ (M-H) 882.2727, found 882.2715.

Neu5Gca2–8Kdna2–3Lac (12): 28 mg, yield 78%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.21–3.26 (m, 28H), 2.76–2.61 (m, 2H), 1.78–1.66 (m, 2H); ^{13}C NMR (200 MHz, D_2O) δ 176.01, 175.64, 173.78, 173.57, 173.44, 102.61, 101.11, 100.09, 99.99, 95.75, 91.79, 78.51, 78.03, 77.86, 77.42, 75.51, 75.22, 74.80, 74.67, 74.22, 73.79, 73.59, 72.37, 72.27, 71.75, 71.28, 71.14, 70.70, 70.08, 69.48, 69.45, 69.24, 69.17, 68.24, 68.16, 68.11, 67.69, 67.41, 62.50, 61.38, 61.25, 61.09, 61.07, 60.93, 59.99, 52.12, 51.39, 40.60, 39.60. HRMS (ESI) m/z calculated for $\text{C}_{32}\text{H}_{52}\text{NO}_{28}$ (M-H) 898.2676, found 898.2663.

Kdna2–8Kdna2–3Lac (13): 24 mg, yield 81%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.63 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 0.4H), 4.48 (d, J = 8.0 Hz, 0.6H), 4.18–3.24 (m, 26H), 2.67 (dd, J = 12.0 and 4.8 Hz, 1H), 2.61 (dd, J = 12.0 and 4.8 Hz, 1H), 1.76 (t, J = 12.0 Hz, 1H), 1.68 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 173.88, 173.45, 102.55, 95.66, 91.70, 77.97, 77.82, 77.70, 75.36, 75.11, 74.95, 74.70, 74.14, 73.70, 73.59, 71.84, 71.19, 71.05, 70.41, 70.31, 70.00, 69.66, 69.39, 69.34, 69.15, 67.70, 67.34, 62.50, 61.26, 60.96, 59.90, 59.75, 39.12. HRMS (ESI) m/z calculated for $\text{C}_{30}\text{H}_{49}\text{O}_{27}$ (M-H) 841.2461, found 841.2464.

General procedures for OPME synthesis of GM2 (4 compounds, 14–17) and GD2 glycans (8 compounds, 18–25)—A GM3 or GD3 glycan (10 mM, 1 eq.) as an acceptor substrate, GalNAc (1.5 eq.), ATP (1.5 eq.), UTP (1.5 eq.), and MgCl_2 (20 mM) were incubated at 37 °C in Tris-HCl buffer (100 mM, pH 7.5) containing BLNahK (3 mg/mL), PmGlmU (3 mg/mL), CjCgtA (lysate, 4.0 mg/mL), and PmPpA (2 mg/mL). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for 2 days with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, alkaline phosphatase (10–20 mg) was added to the reaction mixture which was incubated in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The reaction was then quenched by adding the same volume of ice-cold ethanol and incubated at 4 °C for 30 min. The mixture was centrifuged and the precipitates were removed. The supernatant was concentrated, passed through a BioGel P-2 gel filtration column, and eluted with water to obtain crude sialosides. The fractions containing the product were collected, concentrated, and further purified by HPLC over a XBridge BEH Amide Column (130 Å, 5 μm , 4.6 mm $\times$ 250 mm). Mobile phase A: 100 mM ammonium formate, pH 3.46; Mobile phase B: acetonitrile; Gradient: 65% to 50% B over 25 minutes, 50% to 0% B over 1 minute, 0% B for 2 minutes, 0% to 65% B over 2 minutes, 65% B for 5 minutes. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing pure product were collected and lyophilized to obtain the desired GM2 and GD2 glycans (yields 90–99%).

Neu5Ac α 2–3(GalNAc β 1–4)Lac (14): 211 mg, yield 99%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.73 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.52 (d, J = 8.0 Hz, 1H), 4.16–3.25 (m, 25H), 2.65 (dd, J = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 2.01 (s, 3H), 1.91 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.89, 174.71, 173.97, 102.63, 102.45, 102.41, 101.50, 95.63, 91.68, 78.45, 78.37, 77.05, 74.65, 74.59, 74.23, 74.20, 73.89, 73.61, 72.94, 72.16, 71.27, 71.14, 70.96, 69.94, 69.90, 68.58, 67.87, 67.65, 62.70, 61.04, 60.45, 59.98, 59.84, 52.21, 51.47, 36.82, 22.49, 21.94. HRMS (ESI) m/z calcd for $\text{C}_{31}\text{H}_{51}\text{N}_2\text{O}_{24}$ (M-H) 835.2832, found 835.2821. NMR data were consistent with those reported in the literature.⁸²

Neu5Gca2–3(GalNAc β 1–4)Lac (15): 114 mg, yield 99%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.5H), 4.74 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.5H), 4.52 (d, J = 8.0 Hz, 1H), 4.15 (m, 1H), 4.11 (s, 2H), 3.96–3.25 (m, 25H), 2.67 (dd, J = 12.0 and 4.8 Hz, 1H), 2.01 (s, 3H), 1.93 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.64, 174.71, 173.99, 102.63, 102.45, 102.41, 101.51, 95.63, 78.45, 78.37, 77.03, 74.65, 74.59, 74.23, 74.21, 74.20, 73.90, 73.61, 72.66, 72.23, 71.27, 71.14, 70.96, 69.95, 69.90, 68.33, 67.79, 67.65, 62.66, 61.04, 60.87, 60.45, 59.98, 52.22, 51.18, 36.89, 22.50. HRMS (ESI) m/z calcd for $\text{C}_{31}\text{H}_{51}\text{N}_2\text{O}_{25}$ (M-H) 851.2781, found 851.2770.

Kdna2–3(GalNAc β 1–4)Lac (16): 27 mg, yield 99%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.72 (d, J = 8.0 Hz, 1H), 4.63 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 1H), 4.01–3.23 (m, 25H), 2.59 (dd, J = 12.0 and 4.8 Hz, 1H), 1.99 (s, 3H), 1.85 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.70, 174.12, 170.54, 102.60, 102.43, 102.39, 101.50, 95.62, 91.67, 78.38, 78.30, 76.95, 74.63, 74.58, 74.21, 74.14, 73.91, 73.85, 73.60, 72.41, 71.25, 71.09, 70.96, 70.45, 69.93, 69.87, 69.51, 67.64, 67.44, 62.76, 61.05, 60.38, 59.95, 52.20, 36.39, 22.47. HRMS (ESI) m/z calcd for $\text{C}_{29}\text{H}_{48}\text{NO}_{24}$ (M-H) 794.2566, found 794.2571.

Neu5Ac8OMea2–3(GalNAc β 1–4)Lac (17): 6 mg, yield 95%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 1H), 4.47 (d, J = 8.0 Hz, 1H), 4.15–3.24 (m, 25H), 3.47 (s, 3H), 2.62 (dd, J = 12.0 and 4.8 Hz, 1H), 2.03 (s, 3H), 2.01 (s, 3H), 1.79 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.84, 174.75, 173.43, 102.61, 102.55, 100.51, 95.63, 80.33, 78.23, 76.23, 74.73, 74.69, 74.43, 74.16, 74.13, 73.61, 72.43, 70.99, 69.74, 68.19, 67.59, 66.93, 60.87, 60.51, 59.34, 57.57, 52.37, 51.96, 38.76, 22.42, 21.96. HRMS (ESI) m/z calcd for $\text{C}_{32}\text{H}_{53}\text{N}_2\text{O}_{24}$ (M-H) 849.2988, found 849.2975.

Neu5Ac α 2–8Neu5Ac α 2–3(GalNAc β 1–4)Lac (18): 150 mg, yield 99%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.18–3.25 (m, 32H), 2.75 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 2.03 (s, 3H), 2.02 (s, 3H), 1.76 (t, J = 12.0 Hz, 1H), 1.72 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.95, 174.90, 174.82, 173.35, 173.28, 102.68, 100.50, 95.75, 95.73, 91.79, 91.76, 78.27, 78.23, 78.15, 75.87, 74.79, 74.48, 74.42, 74.21, 73.73, 73.68, 72.61, 71.73, 71.26, 71.08, 70.81, 70.09, 69.65, 69.27, 69.23, 68.44, 68.07, 67.70, 67.66, 62.52, 61.45, 60.91, 60.61, 59.97, 59.82, 59.30, 52.44, 52.33, 51.72, 40.41,

39.15, 22.53, 22.33, 22.03. HRMS (ESI) m/z calcd for $C_{42}H_{68}N_3O_{32}$ (M-H) 1126.3786, found 1126.3770.

Neu5Gca2–8Neu5Aca2–3(GalNAc β 1–4)Lac (19): 32 mg, yield 97%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.19–4.12 (m, 3H), 4.10 (s, 2H), 4.03–3.24 (m, 29H), 2.76 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 2.04 (s, 3H), 1.76 (t, J = 12.0 Hz, 1H), 1.74 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.62, 174.83, 174.75, 173.31, 173.22, 102.62, 102.60, 100.43, 95.66, 93.47, 93.44, 78.19, 78.16, 78.08, 75.82, 75.80, 74.71, 74.40, 74.34, 74.14, 73.65, 73.61, 72.25, 71.70, 71.57, 71.19, 71.01, 70.74, 70.02, 69.59, 69.16, 68.33, 68.12, 68.01, 67.92, 67.60, 67.29, 62.40, 61.37, 61.07, 60.86, 60.83, 60.53, 59.90, 52.36, 52.25, 51.33, 49.85, 49.81, 40.40, 22.44, 22.24, 21.94. HRMS (ESI) m/z calcd for $C_{42}H_{68}N_3O_{33}$ (M-H) 1142.3735, found 1142.3749.

Kdna2–8Neu5Aca2–3(GalNAc β 1–4)Lac (20): 16 mg, yield 96%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.4H), 4.67 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.48 (d, J = 8.0 Hz, 0.4H), 4.47 (d, J = 8.0 Hz, 0.6H), 4.17–4.01 (m, 4H), 3.96–3.24 (m, 28H), 2.70–2.65 (m, 2H), 2.05 (s, 3H), 2.03 (s, 3H), 1.75 (t, J = 12.0 Hz, 1H), 1.68 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.89, 174.81, 173.57, 173.29, 160.99, 102.67, 100.49, 100.48, 95.74, 95.72, 78.19, 78.13, 75.84, 74.77, 74.47, 74.40, 74.19, 73.67, 73.60, 71.99, 71.06, 70.79, 70.35, 69.76, 69.63, 69.27, 69.22, 68.07, 67.67, 62.42, 61.42, 60.90, 60.58, 52.31, 39.98, 39.94, 34.17, 22.51, 22.31. HRMS (ESI) m/z calcd for $C_{40}H_{65}N_2O_{32}$ (M-H) 1085.3520, found 1085.3508.

Neu5Aca2–8Neu5Gca2–3(GalNAc β 1–4)Lac (21): 51 mg, yield 94%; white solid. 1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.4H), 4.67 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.48 (d, J = 8.0 Hz, 0.4H), 4.47 (d, J = 8.0 Hz, 0.6H), 4.18 (d, J = 16.8 Hz, 1H), 4.17–4.09 (m, 3H), 4.08 (d, J = 16.8 Hz, 1H), 4.03–3.24 (m, 29H), 2.73 (dd, J = 12.0 and 4.8 Hz, 1H), 2.68 (dd, J = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 2.00 (s, 3H), 1.77 (t, J = 12.0 Hz, 1H), 1.70 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 177.01, 175.95, 174.87, 174.84, 174.73, 174.58, 173.58, 173.19, 172.49, 102.63, 102.61, 101.89, 100.44, 100.42, 100.05, 96.46, 95.65, 91.68, 78.40, 78.15, 78.06, 75.85, 75.82, 75.05, 74.70, 74.41, 74.32, 74.14, 74.13, 73.63, 73.33, 72.68, 72.48, 71.98, 71.64, 71.17, 70.98, 70.72, 70.12, 69.99, 69.57, 69.46, 68.88, 68.29, 68.28, 68.00, 67.84, 67.58, 67.52, 67.44, 66.81, 62.43, 61.27, 61.00, 60.81, 60.69, 60.50, 60.11, 59.88, 59.73, 52.34, 52.20, 52.06, 51.61, 51.53, 40.89, 40.46, 39.11, 39.02, 22.43, 22.04, 21.92, 21.91. HRMS (ESI) m/z calcd for $C_{42}H_{68}N_3O_{33}$ (M-H) 1142.3735, found 1142.3755.

Neu5Gca2–8Neu5Gca2–3(GalNAc β 1–4)Lac (22): 36 mg, yield 96%; white solid. 1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 0.4H), 4.48 (d, J = 8.0 Hz, 0.6H), 4.18 (d, J = 16.8 Hz, 1H), 4.17–4.14 (m, 2H), 4.11 (m, 1H), 4.09 (s, 2H), 4.08 (d, J = 16.8 Hz, 1H), 4.03–3.24 (m, 29H), 2.75 (dd, J = 12.0 and 4.8 Hz, 1H), 2.68 (dd, J = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 1.77 (t, J = 12.0 Hz, 1H), 1.72 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200

MHz, D₂O) δ 175.96, 175.61, 174.74, 173.62, 173.19, 102.63, 102.61, 100.45, 100.06, 95.65, 91.69, 78.40, 78.15, 78.07, 75.86, 74.70, 74.42, 74.32, 74.13, 73.63, 73.34, 72.20, 71.70, 70.99, 70.73, 70.00, 69.58, 69.46, 68.87, 68.03, 67.93, 67.59, 67.53, 62.40, 61.28, 61.01, 60.84, 60.81, 60.51, 59.89, 52.35, 52.07, 51.32, 40.53, 22.43. HRMS (ESI) m/z calcd for C₄₂H₆₈N₃O₃₄ (M-H) 1158.3684, found 1158.3690.

Kdna2-8Neu5Gca2-3(GalNAc β 1-4)Lac (23): 46 mg, yield 94%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.4H), 4.67 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.48 (d, J = 8.0 Hz, 0.4H), 4.47 (d, J = 8.0 Hz, 0.6H), 4.17 (d, J = 16.8 Hz, 1H), 4.16–4.13 (m, 2H), 4.08 (d, J = 16.8 Hz, 1H), 4.07 (m, 1H), 4.01 (m, 1H), 3.95–3.23 (m, 28H), 2.70–2.66 (m, 2H), 2.02 (s, 3H), 1.76 (t, J = 12.0 Hz, 1H), 1.66 (t, J = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 175.97, 174.73, 173.79, 173.18, 102.62, 100.42, 100.41, 100.05, 95.65, 78.35, 78.15, 78.07, 75.81, 74.70, 74.42, 74.32, 74.14, 74.12, 73.63, 73.50, 73.35, 71.94, 70.99, 70.72, 70.19, 69.68, 69.56, 69.46, 68.88, 67.64, 67.58, 67.52, 62.50, 61.27, 61.00, 60.83, 60.50, 52.35, 52.06, 48.58, 40.07, 25.99, 22.44. HRMS (ESI) m/z calcd for C₄₀H₆₅N₂O₃₃ (M-H) 1101.3470, found 1101.3478.

Neu5Gca2-8Kdna2-3(GalNAc β 1-4)Lac (24): 12 mg, yield 90%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.19 (d, J = 3.2 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 0.4H), 4.48 (d, J = 8.0 Hz, 0.6H), 4.28–3.24 (m, 34H), 2.75 (dd, J = 12.0 and 4.8 Hz, 1H), 2.68 (dd, J = 12.0 and 4.8 Hz, 1H), 2.03 (s, 3H), 1.74–1.69 (m, 2H); ¹³C NMR (200 MHz, D₂O) δ 175.57, 175.66, 174.44, 173.60, 103.61, 102.49, 102.43, 95.67, 91.72, 79.92, 78.29, 78.16, 77.81, 77.71, 75.73, 75.64, 75.17, 75.08, 74.75, 74.72, 74.59, 74.17, 73.71, 73.24, 72.23, 71.69, 71.31, 71.23, 71.06, 70.52, 70.10, 70.03, 69.37, 69.17, 69.11, 68.69, 68.02, 67.76, 67.64, 67.44, 62.45, 61.51, 61.07, 61.00, 60.84, 59.92, 59.83, 52.41, 51.96, 51.31, 51.22, 40.49, 38.96, 22.30. HRMS (ESI) m/z calcd for C₄₀H₆₅N₂O₃₃ (M-H) 1101.3470, found 1101.3455.

Kdna2-8Kdna2-3(GalNAc β 1-4)Lac (25): 8 mg, yield 95%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.47 (d, J = 8.0 Hz, 1H), 4.18–3.24 (m, 32H), 2.67 (dd, J = 12.0 and 4.8 Hz, 1H), 2.61 (dd, J = 12.0 and 4.8 Hz, 1H), 2.01 (s, 3H), 1.75 (t, J = 12.0 Hz, 1H), 1.72 (t, J = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 174.73, 173.96, 173.41, 135.18, 102.59, 100.68, 100.49, 95.64, 91.68, 78.10, 77.78, 75.96, 74.72, 74.69, 74.36, 74.32, 74.13, 73.62, 73.57, 71.86, 71.18, 70.98, 70.76, 70.50, 70.32, 70.24, 69.99, 69.67, 69.59, 69.46, 69.37, 67.70, 67.58, 63.44, 62.50, 61.21, 60.80, 60.55, 59.91, 52.34, 42.51, 39.15, 38.42, 34.11, 22.42. HRMS (ESI) m/z calcd for C₃₈H₆₂NO₃₂ (M-H) 1044.3255, found 1044.3186.

General procedures for OPME synthesis of GM1 (4 compounds, 26–29) and GD1 glycans (5 compounds, 30–34)—A GM2 or GD2 glycan (10 mM, 1 eq.) as an acceptor and Gal (1.1 eq.) were incubated at 37 °C in Tris-HCl buffer (100 mM, pH 7.5) containing ATP (1.2 eq.), UTP (1.2 eq.), MgCl₂ (10 mM), EcGalK (3 mg/mL), BLUSP (3 mg/mL), CjCgtB (2.5 mg/mL), and PmPpA (2 mg/mL). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for overnight with agitation at 100

rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, alkaline phosphatase (10–20 mg) was added to the reaction mixture and the mixture was incubated in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The reaction was then quenched by adding the same volume of ice-cold ethanol and incubated at 4 °C for 30 min. The mixture was then centrifuged and the precipitates were removed. The supernatant was concentrated, passed through a BioGel P-2 gel filtration column, and eluted with water to obtain sialoside mixtures. The fractions containing the product were collected, concentrated, and further purified by HPLC with a XBridge BEH Amide Column (130Å, 5 µm, 4.6 mm × 250 mm). Mobile phase A: 100 mM ammonium formate, pH 3.46; Mobile phase B: acetonitrile; Gradient: 65% to 50% B over 25 minutes, 50% to 0% B over 1 minute, 0% B for 2 minutes, 0% to 65% B over 2 minutes, 65% B for 5 minutes. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing the pure product were collected and lyophilized to produce the desired GM1 and GD1b glycans (yields 80–90%).

Neu5Acα2–3(Galβ1–3GalNAcβ1–4)Lac (26): 140 mg, yield 90%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.21 (d, *J* = 4.0 Hz, 0.4H), 4.76 (d, *J* = 8.0 Hz, 1H), 4.65 (d, *J* = 8.0 Hz, 0.6H), 4.52 (d, *J* = 8.0 Hz, 1H), 4.51 (d, *J* = 8.0 Hz, 1H), 4.10 (s, 2H), 4.15–3.24 (m, 31H), 2.66 (dd, *J* = 12.0 and 4.8 Hz, 1H), 2.00 (s, 3H), 1.92 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 174.97, 174.72, 174.07, 104.68, 102.51, 102.47, 101.58, 95.72, 91.77, 80.28, 78.51, 78.44, 77.10, 74.84, 74.72, 74.38, 74.31, 74.28, 74.03, 73.69, 73.02, 72.45, 72.23, 71.36, 71.04, 70.64, 70.02, 69.97, 68.65, 68.56, 68.53, 67.96, 67.85, 62.78, 61.07, 60.90, 60.60, 60.07, 59.92, 51.57, 51.14, 36.91, 22.56, 22.05. HRMS (ESI) *m/z* calcd for C₃₇H₆₁N₂O₂₉ (M-H) 997.3360, found 997.3349.

Neu5Gcα2–3(Galβ1–3GalNAcβ1–4)Lac (27): 51 mg, yield 86%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.20 (d, *J* = 4.0 Hz, 0.4H), 4.76 (d, *J* = 8.0 Hz, 1H), 4.65 (d, *J* = 8.0 Hz, 0.6H), 4.52 (d, *J* = 8.0 Hz, 1H), 4.51 (d, *J* = 8.0 Hz, 1H), 4.51 (d, *J* = 8.0 Hz, 0.6H), 4.16–3.25 (m, 31H), 2.65 (dd, *J* = 12.0 and 4.8 Hz, 1H), 2.02 (s, 3H), 1.99 (s, 3H), 1.92 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 175.71, 174.72, 174.09, 104.67, 102.49, 102.45, 102.41, 101.58, 95.71, 91.76, 80.28, 78.50, 78.42, 77.06, 74.83, 74.71, 74.29, 74.03, 74.02, 73.69, 73.66, 72.73, 72.43, 72.28, 71.02, 70.62, 69.97, 69.95, 68.56, 68.49, 68.41, 68.37, 67.85, 67.82, 62.73, 62.69, 61.05, 60.94, 60.89, 60.87, 60.58, 60.05, 59.91, 51.28, 51.24, 51.14, 36.98, 36.93, 22.56. HRMS (ESI) *m/z* calcd for C₃₇H₆₁N₂O₃₀ (M-H) 1013.3309, found 1013.3318.

Kdα2–3(Galβ1–3GalNAcβ1–4)Lac (28): 5 mg, yield 87%; white solid. ¹H NMR (800 MHz, D₂O) δ 5.20 (d, *J* = 4.0 Hz, 0.4H), 4.76 (d, *J* = 8.0 Hz, 1H), 4.64 (d, *J* = 8.0 Hz, 0.6H), 4.52 (d, *J* = 8.0 Hz, 1H), 4.50 (d, *J* = 8.0 Hz, 1H), 4.17–3.23 (m, 31H), 2.59 (dd, *J* = 12.0 and 4.8 Hz, 1H), 1.98 (s, 3H), 1.86 (t, *J* = 12.0 Hz, 1H); ¹³C NMR (200 MHz, D₂O) δ 174.73, 174.15, 104.61, 104.15, 102.42, 102.36, 95.62, 78.31, 76.93, 74.90, 74.74, 74.63, 74.22, 74.15, 73.93, 73.59, 72.40, 72.35, 71.25, 70.95, 70.90, 70.54, 70.46, 69.92, 69.87, 69.52, 68.44, 67.77, 67.45, 62.75, 60.99, 60.79, 60.44, 59.96, 36.37, 22.45. HRMS (ESI) *m/z* calcd for C₃₅H₅₈NO₂₉ (M-H) 956.3094, found 956.3088.

Neu5Ac8OMe α 2-3(Gal β 1-3GalNAc β 1-4)Lac (29): 2 mg, yield 80%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 1H), 4.47 (d, J = 8.0 Hz, 1H), 4.42 (d, J = 8.0 Hz, 2H), 4.20–3.24 (m, 31H), 3.41 (s, 3H), 2.54 (dd, J = 12.0 and 4.8 Hz, 1H), 1.95 (s, 3H), 1.94 (s, 3H), 1.74 (t, J = 12.0 Hz, 1H); HRMS (ESI) m/z calcd for $\text{C}_{38}\text{H}_{63}\text{N}_2\text{O}_{29}$ (M-H) 1011.3516, found 1011.3521.

Neu5Ac α 2-8Neu5Ac α 2-3(Gal β 1-3GalNAc β 1-4)Lac (30): 12 mg, yield 88%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.73 (d, J = 8.0 Hz, 0.4H), 4.48 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 0.4H), 4.49 (d, J = 8.0 Hz, 0.6H), 4.17–3.24 (m, 38H), 2.74 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 2.01 (s, 3H), 2.00 (s, 3H), 1.77 (t, J = 12.0 Hz, 1H), 1.71 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.86, 174.81, 174.71, 173.29, 173.28, 104.52, 102.58, 102.29, 95.65, 79.70, 78.17, 78.05, 75.85, 74.80, 74.70, 74.38, 74.14, 73.98, 73.59, 72.52, 72.33, 71.65, 71.20, 71.00, 70.54, 69.60, 69.14, 69.11, 68.47, 68.44, 68.36, 68.01, 67.98, 67.68, 62.43, 61.32, 60.81, 60.76, 60.55, 59.87, 52.23, 51.62, 51.21, 40.32, 22.41, 22.22, 21.91. HRMS (ESI) m/z calcd for $\text{C}_{48}\text{H}_{78}\text{N}_3\text{O}_{37}$ (M-H) 1288.4314, found 1288.4320.

Neu5Gc α 2-8Neu5Ac α 2-3(Gal β 1-3GalNAc β 1-4)Lac (31): 8 mg, yield 85%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.74 (d, J = 8.0 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 1H), 4.48 (d, J = 8.0 Hz, 1H), 4.16–3.25 (m, 40H), 2.76 (dd, J = 12.0 and 4.8 Hz, 1H), 2.66 (dd, J = 12.0 and 4.8 Hz, 1H), 2.05 (s, 3H), 2.01 (s, 3H), 1.76 (t, J = 12.0 Hz, 1H), 1.73 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.61, 174.81, 174.71, 173.29, 173.28, 104.53, 102.58, 102.29, 95.65, 79.71, 78.15, 78.06, 75.85, 74.80, 74.70, 74.39, 74.15, 73.99, 73.60, 72.34, 72.24, 71.71, 71.19, 71.00, 70.54, 69.61, 69.12, 68.46, 68.10, 68.02, 67.91, 67.69, 62.40, 61.32, 60.84, 60.56, 52.23, 51.33, 51.22, 40.38, 22.41, 22.22. HRMS (ESI) m/z calcd for $\text{C}_{48}\text{H}_{78}\text{N}_3\text{O}_{38}$ (M-H) 1304.4263, found 1304.4241.

Neu5Gc α 2-8Neu5Gc α 2-3(Gal β 1-3GalNAc β 1-4)Lac (32): 6 mg, yield 86%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.74 (d, J = 8.0 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.51 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.21–3.24 (m, 42H), 2.76 (dd, J = 12.0 and 4.8 Hz, 1H), 2.68 (dd, J = 12.0 and 4.8 Hz, 1H), 2.03 (s, 3H), 1.78 (t, J = 12.0 Hz, 1H), 1.71 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.97, 175.63, 174.71, 173.63, 173.27, 104.53, 104.15, 102.60, 102.31, 95.65, 79.71, 78.37, 78.08, 75.92, 74.80, 74.70, 74.42, 74.15, 73.99, 73.64, 73.34, 72.34, 72.21, 71.73, 71.20, 71.00, 70.54, 70.00, 69.61, 68.87, 68.46, 68.02, 67.95, 67.69, 67.55, 62.42, 61.26, 61.01, 60.84, 60.81, 60.76, 60.55, 52.07, 51.33, 51.22, 40.52, 22.42. HRMS (ESI) m/z calcd for $\text{C}_{48}\text{H}_{78}\text{N}_3\text{O}_{39}$ (M-H) 1320.4212, found 1320.4232.

Kdn α 2-8Neu5Gc α 2-3(Gal β 1-3GalNAc β 1-4)Lac (33): 3 mg, yield 85%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.74 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.51 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.20–3.24 (m, 40H), 2.68 (dd, J = 12.0 and 4.8 Hz, 2H), 2.01 (s, 3H), 1.78 (t, J = 12.0 Hz, 1H), 1.67 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.99, 174.71, 173.80, 173.26, 104.53, 102.61, 102.31,

95.65, 79.72, 78.34, 78.10, 74.79, 74.70, 74.42, 74.14, 73.98, 73.63, 73.49, 73.35, 72.33, 71.96, 71.19, 70.54, 70.19, 70.00, 69.69, 69.60, 68.85, 68.46, 67.66, 67.55, 62.52, 61.24, 61.00, 60.81, 60.76, 52.07, 40.08, 22.41. HRMS (ESI) m/z calcd for $C_{46}H_{75}N_2O_{38}$ (M-H) 1263.3998, found 1263.4009.

Kdna2–8Kdna2–3(Galβ1–3GalNAcβ1–4)Lac (34): 3 mg, yield 83%; white solid. 1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.74 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.51 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.18–3.24 (m, 38H), 2.65 (dd, J = 12.0 and 4.8 Hz, 2H), 2.01 (s, 3H), 1.75 (t, J = 12.0 Hz, 1H), 1.74 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 174.70, 174.69, 173.98, 173.48, 104.56, 102.59, 102.30, 100.69, 95.65, 91.69, 79.78, 78.22, 78.15, 77.76, 76.06, 74.78, 74.73, 74.70, 74.36, 74.16, 73.99, 73.62, 73.57, 72.35, 71.87, 71.20, 70.98, 70.55, 70.52, 70.34, 69.99, 69.69, 69.63, 69.39, 68.47, 67.73, 62.53, 61.20, 60.81, 60.75, 60.54, 59.93, 51.20, 39.16, 38.35, 22.42. HRMS (ESI) m/z calcd for $C_{44}H_{72}NO_{37}$ (M-H) 1206.3783, found 1206.3774.

One-pot four-enzyme preparative-scale synthesis of GlcNAcβ1–3Lac (35)—Lactose (0.90 g, 2.63 mmol, 40.5 mM), GlcNAc (0.756 g, 3.42 mmol), ATP (1.88 g, 3.42 mmol), and UTP (1.99 g, 3.42 mmol) were dissolved in Tris-HCl buffer (65 mL, pH 8.0) containing $MgCl_2$ (20 mM). BLNahK (19.0 mg), PmGlmU (8.0 mg), NmLgtA (6.0 mg), and PmPpA (4–5 mg) were added. The reactions were carried out by incubating the reaction mixture in an incubator shaker at 37 °C for 48 h. The product formation was monitored by TLC (EtOAc:MeOH:H₂O:HOAc = 4:2:1:0.2 and detected by *p*-anisaldehyde sugar stain) and mass spectrometry (MS). Upon completion, to the reaction was added the same volume (65 mL) of ethanol and the mixture was incubated at 4 °C for 30 min. After centrifugation, the supernatant was concentrated and passed through a Bio Gel P-2 gel filtration column (water was used as an eluant). The fractions containing the product were collected, concentrated, and further purified by silica gel column (EtOAc:MeOH:H₂O, 5:2:1) to obtain trisaccharide GlcNAcβ1–3Lac (35) (1.35 g, 94%). 1H NMR (800 MHz, D_2O) δ 5.19 (d, J = 4.0 Hz, 0.4H), 4.66 (d, J = 8.0 Hz, 0.4H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.41 (d, J = 8.0 Hz, 1H), 4.12 (d, J = 3.2 Hz, 1H), 3.93–3.24 (m, 17H), 2.01 (s, 3H). ^{13}C NMR (200 MHz, D_2O) β -isomer: δ 174.87, 102.84, 102.75, 95.66, 81.87, 78.21, 75.57, 74.80, 74.71, 74.20, 73.71, 73.49, 70.03, 69.92, 68.26, 60.88, 60.41, 60.01, 56.58, 22.09. HRMS (ESI) m/z calculated for $C_{20}H_{36}NO_{16}$ (M+H) 546.2034, found 546.2050. NMR data were consistent with those reported in the literature.⁶⁴

One-pot four-enzyme preparative-scale synthesis of Galβ1–4GlcNAcβ1–3Lac (36)—Trisaccharide GlcNAcβ1–3Lac (1.0 g, 1.83 mmol, 22.9 mM), galactose (0.43 g, 2.38 mmol), ATP (1.40 g, 2.38 mmol), and UTP (1.58 g, 2.38 mmol) were dissolved in Tris-HCl buffer (80 mL, 100 mM, pH 8.0) containing $MgCl_2$ (20 mM), EcGalK (20.0 mg), BLUSP (20 mg), NmLgtB (15 mg), and PpA (20 mg). The reactions were carried out by incubating the reaction mixture in an incubator shaker at 37 °C for 30 h. The product formation was monitored by TLC (*n*-PrOH:H₂O:NH₄OH = 5:2:1 and detected by *p*-anisaldehyde sugar stain) and mass spectrometry (MS). When an optimal yield was achieved, to the reaction mixture was added the same volume (80 mL) of ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was

concentrated and purified by a Bio Gel P-2 gel column (water as eluent). Further purification was achieved by silica gel chromatography (EtOAc:MeOH:H₂O = 5:3:1.5, by volume) to obtain Galβ1-4GlcNAcβ1-3Lac (**36**) (1.28 g, 99%). ¹H NMR (800 MHz, D₂O) δ 5.17 (d, *J* = 4.0 Hz, 0.4H), 4.66 (d, *J* = 8.0 Hz, 0.4H), 4.65 (d, *J* = 8.0 Hz, 0.6H), 4.61 (d, *J* = 8.0 Hz, 0.6H), 4.43 (d, *J* = 7.2 Hz, 1H), 4.38 (d, *J* = 8.0 Hz, 1H), 4.11 (d, *J* = 3.2 Hz, 1H), 3.91–3.87 (m, 2H), 3.84–3.22 (m, 21H), 1.98 (s, 3H). ¹³C NMR (200 MHz, D₂O) β-isomer: δ 174.83, 102.79, 102.76, 102.73, 95.61, 81.82, 78.21, 78.11, 75.52 (2C), 74.76, 74.66, 74.22, 73.65, 73.42 (2C), 70.99, 69.88, 68.24, 68.22, 60.85, 60.84, 60.34, 59.93, 56.52, 22.03. HRMS (ESI) *m/z* calculated for C₂₆H₄₆NO₂₁ (M+H) 708.2562, found 708.2586. NMR data were consistent with those reported in the literature.⁶⁴

One-pot three-enzyme preparative-scale synthesis of Galβ1-4(Fuca1-3)GlcNAcβ1-3Lac (46**)**—LNnT (160 mg, 0.23 mmol, 23 mM), L-fucose (74 mg, 0.45 mmol), ATP (250 mg, 0.45 mmol), and GTP (240 mg, 0.45 mmol) were dissolved in Tris-HCl buffer (10 mL, 100 mM, pH 7.5) containing MgCl₂ (20 mM), FKP (3.0 mg), Hpa1-3FT (2.5 mg), and PmPpA (2 mg). The reactions were carried out by incubating the reaction mixture in an incubator shaker at 37 °C for 48 h. The product formation was monitored by TLC (*n*-PrOH:H₂O:NH₄OH = 4:2:1 and detected by *p*-anisaldehyde sugar stain) and mass spectrometry (MS). When an optimal yield was achieved, to the reaction mixture was added the same volume (10 mL) of ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by the centrifuge and the supernatant was concentrated and purified by a Bio Gel P-2 gel column (water was used as an eluant). Further purification was achieved by silica gel chromatography (EtOAc:MeOH:H₂O = 5:3:2, by volume) to obtain Galβ1-4(Fuca1-3)GlcNAcβ1-3Lac (**46**) (181 mg, 94%). ¹H NMR (800 MHz, D₂O) δ 5.17 (d, *J* = 4.0 Hz, 0.3H), 5.08 (d, *J* = 4.0 Hz, 1H), 4.66 (d, *J* = 7.2 Hz, 1H), 4.61 (d, *J* = 8.0 Hz, 0.7H), 4.42 (d, *J* = 8.0 Hz, 1H), 4.39 (d, *J* = 8.0 Hz, 1H), 4.11 (d, *J* = 3.2 Hz, 1H), 3.92–3.22 (m, 27H), 1.98 (s, 3H), 1.13 (d, *J* = 6.4 Hz, 3H). ¹³C NMR (200 MHz, D₂O) β-isomer: δ 174.57, 102.77, 102.43, 101.62, 98.48, 95.59, 81.91, 78.04, 74.95, 74.77, 74.65, 74.59, 74.19, 73.62, 72.87, 72.30, 71.75, 71.24, 70.88, 69.96, 69.81, 69.03, 68.20, 67.53, 66.55, 62.22, 61.37, 60.82, 59.45, 56.80, 22.08, 15.16. HRMS (ESI) *m/z* calculated for C₃₂H₅₅NO₂₅Na (M+Na) 876.2961, found 876.2965.

General procedures for OPME synthesis of sialylated LNnT, LNT, and Le^x pentasaccharides (37–50**)**—LNnT, LNT, or Le^x pentasaccharide (20 mM, 1 eq.), Neu5Ac or a sialic acid precursor (ManNGc, mannose, or ManNAc5OMe, 1.5 eq.) with sodium pyruvate (7.5 eq.) were incubated at 37 °C in a Tris-HCl buffer (100 mM, pH 8.5) containing CTP (1.5 eq.), MgCl₂ (20 mM), NmCSS (1.5 mg/mL), PmST1 M144D (3 mg/mL), with or without PmNanA (0.2 mg/mL, omit if Neu5Ac was used). The reactions were carried out by incubating the solution in an incubator shaker at 37 °C for 1 or 2 days with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, alkaline phosphatase (10–20 mg) was added to the reaction and the mixture was incubated in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The reaction was then quenched by adding the same volume of ice-cold ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was concentrated, passed through a BioGel P-2 gel filtration column,

and eluted with water to obtain sialoside mixtures. The fractions containing the product were collected, concentrated, and further purified by HPLC using a reverse-phase C18 column (10 μ m, 21.2 $\times$ 250 mm) with a flow rate of 10 mL/min using a gradient elution of 0–100% acetonitrile in water containing 0.05% formic acid over 20 minutes. Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: acetonitrile (v/v); Gradient: 0% B for 3 minutes, 0% to 100% B over 12 minutes, 100% B for 2 minutes, then 100% to 0% B over 3 minutes. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing the pure product were collected and concentrated to obtain the desired sialylated lacto- and neolacto-series glycosphingolipid glycans (yields 80–94%).

Neu5Ac α 2–3Gal β 1–4GlcNAc β 1–3Lac (37): 126 mg, yield 93%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.16 (d, J = 3.2 Hz, 0.4H), 4.65 (d, J = 8.0 Hz, 0.4H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.60 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.38 (d, J = 8.0 Hz, 1H), 4.10 (d, J = 3.2 Hz, 1H), 4.06 (dd, J = 3.2 and 9.6 Hz, 1H), 3.91–3.21 (m, 29H), 2.70 (dd, J = 4.8 and 12.8 Hz, 1H), 1.97 (s, 6H), 1.74 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) β -isomer: δ 174.86, 174.77, 173.76, 102.78, 102.69, 102.38, 99.65, 95.59, 81.90, 78.08, 77.77, 75.29, 75.00, 74.73, 74.37, 74.17, 73.59, 72.70, 71.96, 71.60, 71.22, 70.93, 69.81, 69.21, 68.20, 67.88, 67.28, 62.37, 60.87, 59.85, 59.72, 59.61, 56.03, 51.58, 39.92, 22.02, 21.89. HRMS (ESI) m/z calculated for $\text{C}_{37}\text{H}_{61}\text{N}_2\text{O}_{29}$ (M-H) 997.3360, found 997.3364. NMR data were consistent with those reported in the literature.⁶⁴

Neu5Gc α 2–3Gal β 1–4GlcNAc β 1–3Lac (38): 28 yield 91%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.70 (d, J = 8.0 Hz, 1H), 4.66 (d, J = 8.0 Hz, 1H), 4.55 (d, J = 8.0 Hz, 1H), 4.43 (d, J = 8.0 Hz, 1H), 4.15 (d, J = 3.2 Hz, 1H), 4.12 (dd, J = 3.2 and 9.6 Hz, 1H), 4.11 (s, 2H), 3.97–3.28 (m, 29H), 2.77 (dd, J = 4.8 and 12.8 Hz, 1H), 2.02 (s, 3H), 1.81 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 175.75, 174.88, 173.87, 102.87, 102.74, 102.51, 99.79, 95.71, 82.02, 78.23, 77.94, 75.43, 75.14, 74.86, 74.76, 74.51, 74.31, 72.56, 72.10, 71.08, 69.93, 69.35, 68.30, 68.03, 67.96, 61.00, 60.94, 39.64, 22.15. HRMS (ESI) m/z calculated for $\text{C}_{37}\text{H}_{61}\text{N}_2\text{O}_{30}$ (M-H) 1013.3309, found 1013.3292.

Kdna2–3Gal β 1–4GlcNAc β 1–3Lac (39): 27 mg, yield 92%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.52 (d, J = 8.0 Hz, 1H), 4.42 (d, J = 8.0 Hz, 1H), 4.13 (d, J = 3.2 Hz, 1H), 4.07 (dd, J = 3.2 and 9.6 Hz, 1H), 3.95–3.25 (m, 29H), 2.68 (dd, J = 4.8 and 12.8 Hz, 1H), 2.01 (s, 3H), 1.73 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 174.85, 173.99, 102.75, 102.50, 99.75, 95.68, 82.00, 78.20, 77.90, 75.39, 75.13, 74.84, 74.75, 74.49, 74.29, 73.87, 73.73, 72.08, 72.01, 71.07, 70.20, 69.92, 69.68, 69.31, 68.28, 67.64, 62.57, 60.99, 60.93, 55.13, 39.22, 22.14. HRMS (ESI) m/z calculated for $\text{C}_{35}\text{H}_{58}\text{NO}_{29}$ (M-H) 956.3094, found 956.3105.

Neu5Ac8OMe α 2–3Gal β 1–4GlcNAc β 1–3Lac (40): 15 mg, yield 83%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.69 (d, J = 8.0 Hz, 0.4H), 4.68 (d, J = 8.0 Hz, 0.6H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.51 (d, J = 8.0 Hz, 1H), 4.43 (d, J = 8.0 Hz, 1H), 4.21–3.25 (m, 31H), 3.49 (s, 3H), 2.68 (dd, J = 4.8 and 12.8 Hz, 1H), 2.01 (s, 3H), 1.74 (t, J

= 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 174.86, 174.80, 173.52, 102.79, 102.70, 102.67, 102.59, 100.09, 95.63, 81.96, 80.20, 78.25, 78.14, 77.86, 76.26, 75.62, 75.12, 74.77, 74.68, 74.47, 74.23, 71.98, 71.00, 70.57, 69.85, 69.27, 69.07, 68.22, 67.88, 66.84, 60.91, 59.22, 57.40, 55.10, 43.72, 42.92, 39.71, 26.15, 25.70, 22.07, 21.98. HRMS (ESI) m/z calculated for $\text{C}_{38}\text{H}_{63}\text{N}_2\text{O}_{29}$ (M-H) 1011.3516, found 1011.3514.

Neu5Ac α 2-3Gal β 1-3GlcNAc β 1-3Lac (42): 107 mg, yield 94%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.35 (d, J = 3.2 Hz, 0.4H), 4.87 (d, J = 8.8 Hz, 1H), 4.63 (d, J = 8.0 Hz, 1H), 4.57 (d, J = 8.0 Hz, 1H), 4.26 (d, J = 3.2 Hz, 1H), 4.20 (dd, J = 3.2 and 9.6 Hz, 1H), 4.09–3.39 (m, 29H), 2.89 (dd, J = 4.8 and 12.8 Hz, 1H), 2.15 (s, 6H), 1.90 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) β -isomer: δ 175.07, 174.99, 173.88, 103.42, 102.99, 102.95, 99.76, 95.79, 82.29, 81.98, 78.53, 75.30, 74.73, 74.37, 74.17, 73.59, 72.70, 71.96, 71.60, 71.22, 70.93, 69.81, 69.21, 68.20, 67.88, 67.28, 61.07, 60.65, 60.21, 60.09, 54.66, 51.78, 39.87, 22.40, 22.11. HRMS (ESI) m/z calculated for $\text{C}_{37}\text{H}_{61}\text{N}_2\text{O}_{29}$ (M-H) 997.3360, found 997.3368. NMR data were consistent with those reported in the literature.⁸³

Neu5Gc α 2-3Gal β 1-3GlcNAc β 1-3Lac (43): 202 mg, yield 90%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.35 (d, J = 3.2 Hz, 0.4H), 4.88 (d, J = 8.8 Hz, 1H), 4.64 (d, J = 8.0 Hz, 2H), 4.58 (d, J = 8.0 Hz, 0.6H), 4.27 (d, J = 3.2 Hz, 1H), 4.24 (s, 2H), 4.21 (dd, J = 3.2 and 9.6 Hz, 1H), 4.08–3.39 (m, 29H), 2.89 (dd, J = 4.8 and 12.8 Hz, 1H), 2.15 (s, 6H), 1.92 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) β -isomer: δ 175.80, 174.94, 173.90, 103.44, 102.97, 102.52, 99.78, 95.74, 82.04, 81.92, 78.54, 75.36, 74.81, 74.50, 74.25, 73.88, 71.98, 71.55, 71.54, 70.19, 69.15, 69.10, 68.33, 67.35, 67.10, 61.09, 61.01, 60.62, 60.08, 54.62, 51.49, 39.96, 22.41. HRMS (ESI) m/z calculated for $\text{C}_{37}\text{H}_{61}\text{N}_2\text{O}_{30}$ (M-H) 1013.3309, found 1013.3318.

Kdn α 2-3Gal β 1-3GlcNAc β 1-3Lac (44): 31 mg, yield 91%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.71 (d, J = 8.0 Hz, 0.4H), 4.70 (d, J = 8.0 Hz, 0.6H), 4.67 (d, J = 8.0 Hz, 0.6H), 4.47 (d, J = 8.0 Hz, 1H), 4.42 (d, J = 8.0 Hz, 1H), 4.12 (d, J = 4.0 Hz, 1H), 4.04 (dd, J = 3.2 and 9.6 Hz, 1H), 3.94–3.24 (m, 29H), 2.68 (dd, J = 4.8 and 12.8 Hz, 1H), 2.00 (s, 3H), 1.70 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 174.85, 174.00, 103.37, 103.34, 102.88, 102.84, 102.49, 102.43, 99.52, 95.70, 95.67, 91.78, 91.73, 82.01, 81.89, 81.87, 78.34, 78.22, 75.50, 75.48, 75.15, 75.04, 74.84, 74.74, 74.30, 73.78, 73.72, 72.11, 71.07, 70.20, 69.96, 69.66, 69.01, 69.00, 68.37, 68.27, 68.25, 67.61, 67.16, 67.09, 62.47, 62.41, 60.98, 60.92, 39.44, 39.38, 22.26. HRMS (ESI) m/z calculated for $\text{C}_{35}\text{H}_{58}\text{NO}_{29}$ (M-H) 956.3094, found 956.3106.

Neu5Ac8OMe α 2-3Gal β 1-3GlcNAc β 1-3Lac (45): 32 mg, yield 83%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.4H), 4.73 (d, J = 8.0 Hz, 0.4H), 4.72 (d, J = 8.0 Hz, 0.6H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.48 (d, J = 8.0 Hz, 1H), 4.43 (d, J = 8.0 Hz, 1H), 4.15–3.25 (m, 31H), 3.48 (s, 3H), 2.67 (dd, J = 4.8 and 12.8 Hz, 1H), 2.02 (s, 3H), 2.01 (s, 3H), 1.74 (t, J = 12.0 Hz, 1H). ^{13}C NMR (200 MHz, D_2O) δ 181.39, 174.82, 174.74, 173.62, 161.98, 103.08, 102.82, 102.78, 102.43, 100.01, 95.65, 95.62, 81.82, 80.35, 78.17, 75.56, 75.06, 74.92, 74.78, 74.68, 74.24, 71.01, 69.89, 69.16, 68.36, 68.21, 67.95, 67.30, 66.82,

62.79, 62.78, 60.87, 59.32, 57.37, 57.36, 56.42, 51.94, 23.15, 22.22, 21.98. HRMS (ESI) m/z calculated for $C_{38}H_{63}N_2O_{29}$ (M-H) 1011.3516, found 1011.3510.

Neu5Ac α 2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Lac (47): 51 mg, yield 86%; white solid. 1H NMR (800 MHz, D_2O) δ 5.22 (d, J = 4.0 Hz, 0.4H), 5.18 (d, J = 3.2 Hz, 0.4H), 5.12 (d, J = 4.0 Hz, 0.6H), 4.56 (d, J = 8.0 Hz, 0.6H), 4.53 (d, J = 8.0 Hz, 1H), 4.46 (d, J = 8.0 Hz, 0.4H), 4.44 (d, J = 8.0 Hz, 1H), 4.42 (d, J = 8.0 Hz, 0.6H), 4.16 (d, J = 3.2 Hz, 1H), 4.13–3.27 (m, 34H), 2.77 (dd, J = 4.8 and 12.0 Hz, 1H), 2.03 (s, 6H), 1.78 (d, J = 12.0 Hz, 1H), 1.17 (d, J = 6.4 Hz, 3H). ^{13}C NMR (200 MHz, D_2O) β -isomer: δ 174.93, 174.59, 173.77, 102.83, 102.44, 101.47, 99.56, 98.48, 95.64, 82.00, 78.27, 78.17, 77.92, 75.57, 75.07, 74.82, 74.42, 73.68, 72.94, 72.81, 71.81, 71.77, 71.03, 70.02, 69.87, 69.17, 69.08, 68.21, 68.00, 67.61, 67.21, 66.56, 62.50, 61.40, 60.89, 59.97, 59.42, 55.17, 51.60, 39.69, 22.13, 21.94, 15.18. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{33}$ (M-H) 1143.3939, found 1143.3920.

Neu5Gca2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Lac (48): 18 mg, yield 84%; white solid. 1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.3H), 5.11 (d, J = 4.8 Hz, 0.7H), 5.09 (d, J = 4.8 Hz, 0.3H), 4.69 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.7H), 4.52 (d, J = 8.0 Hz, 1H), 4.44 (d, J = 8.0 Hz, 0.3H), 4.42 (d, J = 8.0 Hz, 0.7H), 4.42 (d, J = 8.0 Hz, 1H), 4.15 (d, J = 3.2 Hz, 1H), 4.11 (s, 2H), 4.08 (dd, J = 3.2 and 9.6 Hz, 1H), 3.98–3.25 (m, 33H), 2.77 (dd, J = 4.8 and 12.0 Hz, 1H), 2.00 (s, 3H), 1.80 (t, J = 12.0 Hz, 1H), 1.15 (d, J = 6.4 Hz, 3H). ^{13}C NMR (200 MHz, D_2O) δ 175.66, 174.56, 173.78, 102.79, 102.46, 101.42, 99.54, 98.46, 95.60, 91.67, 81.97, 81.94, 78.21, 78.11, 75.52, 74.89, 74.79, 74.76, 74.67, 74.51, 74.22, 73.64, 72.89, 72.50, 72.12, 71.78, 71.26, 70.98, 69.98, 69.83, 69.14, 69.04, 68.16, 67.92, 67.88, 67.67, 67.57, 67.16, 66.53, 62.41, 61.37, 60.83, 59.93, 59.38, 51.40, 51.26, 48.72, 39.71, 22.11, 15.26, 15.15. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{34}$ (M-H) 1159.3888, found 1159.3898.

Kdna2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Lac (49): 6 mg, yield 83%; white solid. 1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 4.0 Hz, 0.3H), 5.10 (d, J = 4.0 Hz, 0.7H), 5.09 (d, J = 4.0 Hz, 0.3H), 4.69 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.7H), 4.50 (d, J = 8.0 Hz, 1H), 4.44 (d, J = 8.0 Hz, 0.3H), 4.43 (d, J = 8.0 Hz, 0.7H), 4.42 (d, J = 8.0 Hz, 1H), 4.14 (d, J = 3.2 Hz, 1H), 4.04 (dd, J = 3.2 and 9.6 Hz, 1H), 3.97–3.25 (m, 33H), 2.69 (dd, J = 4.8 and 12.0 Hz, 1H), 2.01 (s, 3H), 1.72 (t, J = 12.0 Hz, 1H), 1.15 (d, J = 6.4 Hz, 3H). ^{13}C NMR (200 MHz, D_2O) δ 174.56, 173.91, 102.80, 102.77, 102.46, 101.45, 98.46, 95.60, 91.68, 81.97, 78.21, 78.11, 75.50, 74.90, 74.79, 74.76, 74.67, 74.51, 74.22, 73.81, 73.65, 72.91, 72.04, 71.77, 71.27, 70.99, 70.09, 69.99, 69.83, 69.73, 69.62, 69.12, 69.04, 68.17, 67.57, 67.14, 66.53, 62.51, 61.37, 60.85, 59.93, 59.39, 39.29, 22.11, 15.26, 15.15. HRMS (ESI) m/z calculated for $C_{41}H_{68}NO_{33}$ (M-H) 1102.3674, found 1102.3686.

Neu5Ac8OMe α 2-3Gal β 1-4(Fuca1-3)GlcNAc β 1-3Lac (50): 2 mg, yield, 80%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 5.10 (d, J = 4.0 Hz, 1H), 4.70 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.45 (d, J = 8.0 Hz, 1H), 4.43 (d, J = 8.0 Hz, 1H), 4.41 (d, J = 8.0 Hz, 1H), 4.14–3.25 (m, 35H), 2.65 (m, 1H), 2.01 (s, 6H), 1.68 (m, 1H), 1.15 (d, J = 6.4 Hz, 3H). ^{13}C NMR (200 MHz, D_2O) δ 174.86, 174.84, 174.62, 173.70, 173.54, 102.81, 102.78, 101.68, 101.66, 100.91, 99.90, 98.53, 98.49, 95.61, 91.69, 81.98,

81.95, 80.44, 80.34, 78.24, 78.14, 75.81, 75.05, 74.97, 74.86, 74.77, 74.68, 74.23, 73.65, 73.21, 72.77, 72.74, 72.56, 72.13, 71.92, 71.79, 71.28, 71.00, 70.89, 70.00, 69.84, 69.13, 69.06, 69.00, 68.21, 68.18, 67.87, 67.83, 67.67, 67.58, 67.38, 67.03, 66.80, 66.54, 62.41, 61.36, 60.86, 59.94, 59.81, 59.65, 59.57, 59.23, 57.61, 57.45, 52.06, 51.89, 39.89, 22.12, 21.95, 15.25, 15.17. HRMS (ESI) m/z calculated for $C_{44}H_{73}N_2O_{33}$ (M-H) 1157.4096, found 1157.4084.

General procedures for OPME synthesis of Gb₃ and iGb₃ glycans—Lac (20 mM, 1 eq.), Gal (1.5 eq.) were incubated at 37 °C in 100 mM of Tris-HCl buffer (pH 7.5) containing ATP (1.5 eq.), UTP (1.5 eq.), MgCl₂ (10 mM), MnCl₂ (10 mM), EcGalK (4 mg/mL), BLUSP (4 mg/mL), Ba1–3GalT (6 mg/mL, for preparing iGb₃) or NmLgtC (5 mg/mL, for preparing Gb₃), and PmPpA (3 mg/mL). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, the reaction was quenched by adding the same volume of ice-cold ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was concentrated and purified by silica gel column (EtOAc:MeOH:H₂O, 4:2:1) followed by a Bio-gel P2 gel filtration column to obtain the desired Gb₃ or iGb₃.

Galα1–4Lac (51): 850 mg, yield 95%; white solid. ¹H NMR (800 MHz, D₂O): δ 5.18 (d, J = 4.0 Hz, 0.4H), 4.90 (d, J = 4.0 Hz, 1H), 4.63 (d, J = 8.0 Hz, 0.6H), 4.47 (d, J = 7.2 Hz, 1H), 4.31 (m, 1H), 4.00 (m, 2H), 3.92–3.23 (m, 15H); ¹³C NMR (200 MHz, D₂O): δ 103.41, 103.37, 100.46, 95.86, 91.94, 78.82, 78.71, 77.51, 75.58, 74.99, 74.56, 74.04, 72.30, 71.59, 71.35, 71.06, 70.96, 70.30, 69.28, 69.08, 68.71, 60.65, 60.53, 60.18, 60.06; HRMS: calculated for C₁₈H₃₂O₁₆Na (M + Na) 527.1588, found 527.1613. NMR data were consistent with those reported in the literature.⁸⁴

Galα1–3Lac (52): 790 mg, yield 99%; white solid. ¹H NMR (800 MHz, D₂O): δ 5.21 (d, J = 3.2 Hz, 0.4 H), 5.13 (d, J = 3.2 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6 H), 4.51 (d, J = 8.0 Hz, 1H), 4.17 (m, 2H), 4.00–3.27 (m, 16 H); ¹³C NMR (200 MHz, D₂O) δ 102.71, 102.68, 95.65, 95.31, 95.30, 91.70, 78.53, 78.41, 77.07, 77.05, 74.93, 74.65, 74.31, 73.66, 71.37, 71.00, 70.70, 69.95, 69.46, 69.16, 69.00, 68.09, 64.71, 64.69, 60.90, 60.88, 60.80, 60.03, 59.89. HRMS: calculated for C₁₈H₃₂O₁₆Na (M + Na), 527.1588, found 527.1583. NMR data were consistent with those reported in the literature.⁸⁵

General procedures for OPME synthesis of Gb₄ and iGb₄ glycans—Gb₃ or iGb₃ glycan (20 mM, 1 eq.) as an acceptor and GalNAc (1.5 eq.) were incubated at 37 °C in Tris-HCl buffer (100 mM, pH 7.5) containing ATP (1.5 eq.), UTP (1.5 eq.), MgCl₂ (20 mM), NahK (3 mg/mL), PmGlmU (3 mg/mL), HiLgtD (6 mg/mL), and PmPpA (2 mg/mL). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for 2 days with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, the reaction was quenched by adding the same volume of ice-cold ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was concentrated and purified by silica gel

column (EtOAc:MeOH:H₂O, 5:3:2) followed by a Bio-gel P2 gel filtration column to afford the desired Gb₄ or iGb₄ glycan.

GalNAc β 1–3Gal α 1–4Lac (53): 570 mg, yield 91%; white solid. ¹H NMR (800 MHz, D₂O): δ 5.20 (d, J = 3.2 Hz, 0.4H), 4.89 (d, J = 3.2 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.60 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.37 (m, 1H), 4.23 (bs, 1H), 4.01 (bs, 1H), 3.95–3.22 (m, 21 H), 2.02 (s, 3H); ¹³C NMR (200 MHz, D₂O) δ 175.09, 103.21, 103.15, 100.29, 95.60, 91.64, 78.74, 78.55, 77.09, 77.03, 75.34, 75.32, 74.81, 74.72, 74.32, 73.83, 73.78, 71.98, 71.09, 70.77, 70.76, 70.65, 70.16, 70.12, 68.85, 68.81, 67.67, 67.59, 60.88, 60.26, 60.25, 60.20, 52.61, 22.16. HRMS: calculated for C₂₆H₄₆NO₂₁ (M + H), 708.2562, found 708.2598. NMR data were consistent with those reported in the literature.⁷⁸

GalNAc β 1–3Gal α 1–3Lac (54): 340 mg, yield 92%; white solid. ¹H NMR (800 MHz, D₂O): δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.88 (d, J = 4.0 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.60 (d, J = 8.8 Hz, 1H), 4.49 (d, J = 8.8 Hz, 0.4H), 4.48 (d, J = 8.0 Hz, 0.6H), 4.35 (m, 1H), 4.23 (bs, 1H), 4.00–3.24 (m, 22 H), 2.01 (s, 3H); ¹³C NMR (200 MHz, D₂O) δ 175.08, 103.15, 100.29, 100.22, 99.91, 95.59, 95.54, 91.69, 91.61, 78.73, 78.55, 77.10, 76.98, 75.33, 74.78, 74.71, 74.31, 73.83, 73.75, 71.97, 71.35, 71.07, 70.75, 70.62, 70.16, 70.10, 68.86, 68.78, 67.71, 67.59, 67.53, 60.86, 60.31, 60.25, 60.21, 60.05, 59.80, 52.51, 52.34, 22.17, 22.14. HRMS: calculated for C₂₆H₄₆NO₂₁ (M + H), 708.2562, found 708.2596. NMR data were consistent with those reported in the literature.⁷⁸

General procedures for OPME synthesis of Gb₅ and iGb₅ glycans—Gb₄ or iGb₄ glycan (20 mM, 1 eq.) as an acceptor and Gal (1.1 eq.) were incubated at 37 °C in Tris-HCl buffer (100 mM, pH 7.5) containing ATP (1.2 eq.), UTP (1.2 eq.), MgCl₂ (10 mM), MnCl₂ (10 mM), EcGalK (3 mg/mL), BLUSP (3 mg/mL), CjCgtB (6 mg/mL), and PmPpA (2 mg/mL). The reaction was carried out by incubating the solution in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, alkaline phosphatase (10–20 mg) was added to the reaction mixture and incubated in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The reaction was quenched by adding the same volume of ice-cold ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was concentrated, passed through a BioGel P-2 gel filtration column, and eluted with water to obtain sialoside mixtures. The fractions containing the product were collected, concentrated, and further purified by HPLC using a reverse-phase C18 column (10 μ m, 21.2 $\times$ 250 mm) with a flow rate of 10 mL/min and a gradient elution of 0–100% acetonitrile in water containing 0.05% formic acid over 20 minutes. Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: acetonitrile (v/v); Gradient: 0% B for 3 min, 0% to 100% B over 12 min, 100% B for 2 min, then 100% to 0% B over 3 min. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing the pure product were collected and concentrated to obtain the desired Gb₅ or iGb₅ glycan.

Gal β 1–3GalNAc β 1–3Gal α 1–4Lac (55): 124 mg, yield, 60%; white solid. ¹H NMR (800 MHz, D₂O): δ 5.20 (d, J = 3.2 Hz, 0.4H), 4.89 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.0 Hz, 1H),

4.64 (d, $J = 8.0$ Hz, 0.6H), 4.50 (d, $J = 8.0$ Hz, 1H), 4.43 (d, $J = 8.0$ Hz, 1H), 4.36 (m, 1H), 4.23 (bs, 1H), 4.16–3.24 (m, 28 H), 2.00 (s, 3H); ^{13}C NMR (200 MHz, D_2O) δ 175.01, 104.69, 103.16, 103.13, 102.87, 102.84, 100.27, 95.60, 91.67, 79.46, 78.67, 78.63, 78.58, 78.52, 77.05, 75.32, 74.87, 74.71, 74.47, 74.32, 73.80, 72.31, 71.97, 71.35, 71.09, 70.74, 70.46, 70.13, 70.01, 68.81, 68.44, 67.86, 67.49, 60.87, 60.82, 60.23, 60.18, 59.92, 59.79, 51.34, 22.14. HRMS: calculated for $\text{C}_{32}\text{H}_{55}\text{NNaO}_{26}$ ($M + \text{Na}$), 892.2910, found 892.2898.

Gal β 1–3GalNAc β 1–3Gal α 1–3Lac (56): 110 mg, yield 45%; white solid. ^1H NMR (800 MHz, D_2O): δ 5.20 (d, $J = 4.0$ Hz, 0.4H), 5.09 (d, $J = 4.0$ Hz, 1H), 4.68 (d, $J = 8.0$ Hz, 1H), 4.64 (d, $J = 8.0$ Hz, 0.6H), 4.50 (d, $J = 8.0$ Hz, 1H), 4.43 (d, $J = 8.8$ Hz, 1H), 4.21–3.26 (m, 30 H), 2.00 (s, 3H); ^{13}C NMR (200 MHz, D_2O) δ 175.01, 104.69, 102.76, 102.65, 95.63, 95.51, 91.68, 79.48, 78.70, 78.43, 78.30, 77.05, 74.90, 74.87, 74.64, 74.50, 74.30, 73.65, 72.31, 71.36, 70.98, 70.46, 70.26, 69.94, 69.49, 68.91, 68.44, 67.85, 67.13, 64.72, 60.87, 60.79, 60.66, 60.00, 59.86, 51.39, 22.15. HRMS: calculated for $\text{C}_{32}\text{H}_{55}\text{NNaO}_{26}$ ($M + \text{Na}$), 892.2910, found 892.2930.

General procedures for OPME synthesis of sialylated Gb₅ and iGb₅ glycans—

Gb₅ or iGb₅ (20 mM, 1 eq.) and Neu5Ac or a sialic acid precursor (ManNGc, mannose, or ManNAc5OMe, 1.5 eq.) with sodium pyruvate (7.5 eq.) were incubated at 37 °C in a Tris-HCl buffer (100 mM, pH 8.5) containing CTP (1.5 eq.), MgCl_2 (20 mM), NmCSS (3 mg/mL), PmST1 M144D (4 mg/mL), with or without PmNanA (1.5 mg/mL, omit if Neu5Ac was used). The reactions were carried out by incubating the solution in an incubator shaker at 37 °C for 1 or 2 days with agitation at 100 rpm. The product formation was monitored by LC-MS. When an optimal yield was achieved, alkaline phosphatase (10–20 mg) was added and the reaction mixture was incubated in an incubator shaker at 37 °C for overnight with agitation at 100 rpm. The reaction was then quenched by adding the same volume of ice-cold ethanol and the mixture was incubated at 4 °C for 30 min. The precipitates were removed by centrifugation and the supernatant was concentrated, passed through a BioGel P-2 gel filtration column, and eluted with water to obtain sialoside mixtures. The fractions containing product were collected, concentrated, and further purified by HPLC with a reverse-phase C18 column (10 μm , 21.2 $\times$ 250 mm) with a flow rate of 10 mL/min using a gradient elution of 0–100% acetonitrile in water containing 0.05% formic acid over 20 min. Mobile phase A: 0.05% formic acid in water (v/v); Mobile phase B: acetonitrile (v/v); Gradient: 0% B for 3 min, 0% to 100% B over 12 min, 100% B for 2 min, then 100% to 0% B over 3 min. HPLC purification was monitored by absorption at 210 nm, and glycan-containing fractions were analyzed by TLC and MS. The fractions containing the pure product were collected and concentrated to obtain the desired sialylated lacto- and neolacto-series glycosphingolipid glycans (yields 71–86%).

Neu5Ac α 2–3Gal β 1–3GalNAc β 1–3Gal α 1–4Lac (57): 26 mg, yield 86%; white solid. ^1H NMR (800 MHz, D_2O) δ 5.21 (d, $J = 4.0$ Hz, 0.4H), 4.89 (d, $J = 4.0$ Hz, 1H), 4.67 (d, $J = 8.0$ Hz, 1H), 4.65 (d, $J = 8.0$ Hz, 0.6H), 4.51 (d, $J = 8.0$ Hz, 1H), 4.50 (d, $J = 8.0$ Hz, 1H), 4.37 (m, 1H), 4.24–3.25 (m, 36 H), 2.73 (dd, $J = 4.8$ and 12.0 Hz, 1H), 2.01 (s, 3H), 2.00 (s, 3H), 1.77 (t, $J = 12.0$ Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.99, 174.83, 173.82, 104.44, 103.16, 102.84, 100.26, 99.55, 95.57, 79.67, 78.64, 78.58, 78.52, 77.02, 75.42,

75.32, 74.71, 74.65, 74.48, 74.32, 73.80, 72.66, 71.98, 71.71, 71.35, 71.11, 70.75, 70.14, 70.02, 68.89, 68.81, 68.28, 67.92, 67.72, 67.49, 67.23, 62.35, 60.86, 60.25, 60.18, 51.53, 51.21, 39.59, 22.21, 21.92. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{34}$ (M-H) 1159.3888, found 1159.3907.

Neu5Gca2-3Gal β 1-3GalNAc β 1-3Gala1-4Lac (58): 9 mg, yield 83%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.89 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.36 (m, 1H), 4.23 (bs, 1H), 4.15 (d, J = 3.2 Hz, 1H), 4.09 (s, 2H), 4.07–3.25 (m, 34 H), 2.75 (dd, J = 4.8 and 12.0 Hz, 1H), 2.01 (s, 3H), 1.78 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.60, 174.98, 173.84, 104.45, 103.16, 103.13, 102.84, 100.25, 99.55, 95.57, 91.65, 79.65, 78.64, 78.58, 78.52, 77.02, 75.41, 75.32, 74.71, 74.66, 74.47, 74.32, 73.80, 72.37, 71.97, 71.77, 71.35, 71.10, 70.74, 70.14, 70.02, 68.89, 68.80, 68.00, 67.84, 67.73, 67.49, 67.21, 62.31, 60.84, 60.24, 60.18, 59.92, 51.21, 39.66, 22.21. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{35}$ (M-H) 1175.3837, found 1175.3874.

Kdna2-3Gal β 1-3GalNAc β 1-3Gala1-4Lac (59): 8 mg, yield 85%; white solid. 1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 3.2 Hz, 0.4H), 4.90 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.37 (m, 1H), 4.24 (bs, 1H), 4.15 (d, J = 3.2 Hz, 1H), 4.07–3.26 (m, 34 H), 2.68 (dd, J = 4.8 and 12.0 Hz, 1H), 2.01 (s, 3H), 1.72 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.06, 174.05, 104.56, 103.24, 102.92, 100.33, 99.53, 95.65, 79.66, 78.72, 78.66, 78.60, 77.10, 75.45, 75.40, 74.79, 74.76, 74.56, 74.39, 73.87, 73.77, 72.08, 72.05, 71.42, 71.17, 70.82, 70.21, 70.10, 69.66, 68.93, 68.88, 67.82, 67.63, 67.57, 67.20, 62.47, 61.34, 60.91, 60.32, 60.26, 60.00, 51.30, 39.38, 24.41, 22.29. HRMS (ESI) m/z calculated for $C_{41}H_{68}NO_{34}$ (M-H) 1118.3623, found 1118.3629.

Neu5Ac8OMea2-3Gal β 1-3GalNAc β 1-3Gala1-4Lac (60): 7 mg, yield 78%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 4.89 (d, J = 4.0 Hz, 1H), 4.66 (d, J = 8.0 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.49 (d, J = 8.0 Hz, 1H), 4.48 (d, J = 8.0 Hz, 1H), 4.36 (m, 1H), 4.23–3.25 (m, 36 H), 3.44 (s, 3H), 2.63 (dd, J = 4.8 and 12.0 Hz, 1H), 2.01 (s, 3H), 2.00 (s, 3H), 1.80 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 176.36, 174.94, 174.81, 174.64, 173.75, 173.65, 100.48, 100.26, 100.00, 96.19, 95.56, 80.28, 79.89, 78.53, 74.71, 74.60, 74.46, 74.30, 71.96, 70.75, 70.16, 69.75, 69.45, 69.15, 69.03, 67.93, 67.06, 66.81, 64.92, 62.31, 61.70, 60.82, 60.23, 59.78, 57.74, 57.44, 57.35, 39.49, 21.98, 19.94. HRMS (ESI) m/z calculated for $C_{44}H_{73}N_2O_{34}$ (M-H) 1173.4045, found 1173.4046.

Neu5Acc2-3Gal β 1-3GalNAc β 1-3Gala1-3Lac (61): 40 mg, yield 85%; white solid. 1H NMR (800 MHz, D_2O) δ 5.16 (d, J = 4.0 Hz, 0.4H), 5.05 (d, J = 4.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 1H), 4.61 (d, J = 8.0 Hz, 0.6H), 4.47 (d, J = 8.0 Hz, 1H), 4.46 (d, J = 8.0 Hz, 1H), 4.26–3.21 (m, 37 H), 2.68 (dd, J = 4.8 and 12.0 Hz, 1H), 1.97 (s, 3H), 1.96 (s, 3H), 1.72 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.07, 174.92, 173.87, 104.48, 103.20, 102.88, 100.29, 99.60, 95.61, 79.72, 78.68, 78.63, 78.57, 77.06, 75.47, 75.36, 74.75, 74.69, 74.52, 74.35, 73.84, 72.66, 71.98, 71.71, 71.35, 71.11, 70.75, 70.14, 70.02, 68.89, 68.81,

68.28, 67.92, 67.72, 67.49, 67.23, 62.35, 60.86, 60.25, 60.22, 51.56, 51.24, 39.61, 22.23, 21.94. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{34}$ (M-H) 1159.3888, found 1159.3896.

Neu5Gca2-3Gal β 1-3GalNAc β 1-3Gala1-4Lac (62): 6 mg, yield 84%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 4.0 Hz, 0.4H), 5.09 (d, J = 4.0 Hz, 1H), 4.68 (d, J = 8.0 Hz, 1H), 4.64 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 2H), 4.21 (d, J = 4.0 Hz, 0.4H), 4.18 (m, 1H), 4.15 (d, J = 4.0 Hz, 0.6H), 4.09 (s, 2H), 4.07–3.25 (m, 35 H), 2.75 (dd, J = 4.8 and 12.0 Hz, 1H), 2.00 (s, 3H), 1.78 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 175.61, 174.99, 173.84, 104.44, 102.75, 102.66, 99.56, 95.63, 95.54, 79.66, 78.68, 78.45, 78.32, 77.09, 75.41, 74.90, 74.66, 74.64, 74.50, 74.30, 73.65, 72.37, 71.77, 70.99, 70.27, 69.48, 68.89, 68.00, 67.84, 67.72, 67.13, 62.31, 60.87, 60.83, 60.67, 51.25, 39.66, 22.22. HRMS (ESI) m/z calculated for $C_{43}H_{71}N_2O_{35}$ (M-H) 1175.3837, found 1175.3865.

Kdna2-3Gal β 1-3GalNAc β 1-3Gala1-3Lac (63): 7 mg, yield 82%; white solid. 1H NMR (800 MHz, D_2O) δ 5.20 (d, J = 3.2 Hz, 0.4H), 5.09 (d, J = 4.0 Hz, 1H), 4.68 (d, J = 8.0 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.6H), 4.50 (d, J = 8.0 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.23–3.26 (m, 37 H), 2.68 (dd, J = 4.8 and 12.0 Hz, 1H), 2.00 (s, 3H), 1.71 (t, J = 12.0 Hz, 1H); ^{13}C NMR (200 MHz, D_2O) δ 174.99, 173.98, 104.48, 102.75, 102.67, 99.48, 95.63, 95.54, 79.61, 78.68, 78.46, 78.33, 77.09, 75.38, 74.91, 74.69, 74.65, 74.51, 74.30, 73.70, 73.65, 73.46, 73.37, 73.06, 72.01, 71.36, 70.99, 70.28, 70.14, 69.94, 69.80, 69.59, 69.48, 68.91, 68.86, 67.74, 67.55, 67.14, 64.74, 62.55, 62.40, 60.88, 60.81, 60.68, 51.28, 39.30, 22.23. HRMS (ESI) m/z calculated for $C_{41}H_{68}NO_{34}$ (M-H) 1118.3623, found 1118.3622.

Neu5Ac8OMe α 2-3Gal β 1-3GalNAc β 1-3Gala1-3Lac (64): 1 mg, yield 71%; white solid. 1H NMR (800 MHz, D_2O) δ 5.21 (d, J = 3.2 Hz, 0.5H), 4.89 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.8 Hz, 1H), 4.65 (d, J = 8.0 Hz, 0.5H), 4.50 (d, J = 7.2 Hz, 1H), 4.49 (d, J = 8.0 Hz, 1H), 4.37–3.25 (m, 37 H), 3.45 (s, 3H), 2.64 (dd, J = 4.8 and 12.0 Hz, 1H), 2.02 (s, 3H), 2.00 (s, 3H), 1.81 (t, J = 12.0 Hz, 1H). HRMS (ESI) m/z calculated for $C_{44}H_{73}N_2O_{34}$ (M-H) 1173.4045, found 1173.4025.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institute of General Medical Sciences and the National Cancer Institute of National Institutes of Health Project Number 261201300041C. The plasmid for expressing HiLgtD was a kind gift from Dr. Peng G. Wang in Georgia State University.

References

1. Fang Y. J Am Chem Soc. 2006; 128:3158. [PubMed: 16522092]
2. Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. J Exp Med. 1982; 155:1133. [PubMed: 7061953]
3. Chapman PB, Morrissey DM, Panageas KS, Hamilton WB, Zhan C, Destro AN, Williams L, Israel RJ, Livingston PO. Clin Cancer Res. 2000; 6:874. [PubMed: 10741710]

4. Heimbürg-Molinaro J, Lum M, Vijay G, Jain M, Almogren A, Rittenhouse-Olson K. Vaccine. 2011; 29:8802. [PubMed: 21964054]
5. Padler-Karavani V, Hurtado-Ziola N, Pu M, Yu H, Huang S, Muthana S, Chokhawala HA, Cao H, Secrest P, Friedmann-Morvinski D, Singer O, Ghaderi D, Verma IM, Liu YT, Messer K, Chen X, Varki A, Schwab R. Cancer Res. 2011; 71:3352. [PubMed: 21505105]
6. Hedlund M, Padler-Karavani V, Varki NM, Varki A. Proc Natl Acad Sci U S A. 2008; 105:18936. [PubMed: 19017806]
7. Merrill AH Jr. Chem Rev. 111:6387.
8. Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE. Oncol Rep. 2002; 9:267. [PubMed: 11836591]
9. Fernandez LE, Gabri MR, Guthmann MD, Gomez RE, Gold S, Fainboim L, Gomez DE, Alonso DF. Clin Dev Immunol. 2010; 2010:814397. [PubMed: 21048926]
10. Peguet-Navarro J, Sportouch M, Popa I, Berthier O, Schmitt D, Portoukalian J. J Immunol. 2003; 170:3488. [PubMed: 12646609]
11. Schnaar RL., Suzuki, A., Stanley, P. Essentials of Glycobiology. 2nd. Varki, A.Cummings, RD.Esko, JD.Freeze, HH.Stanley, P.Bertozzi, CR.Hart, GW., Etzler, ME., editors. Cold Spring Harbor Laboratory Press; 2008. p. 129Chapter 10
12. Samuel Tesfay, DS., Hecht, Gail A. Bacterial-Epithelial cell cross-talk. McCormick, BA., editor. Cambridge Press; Cambridge: 2006.
13. Gioannini TL, Weiss JP. Immunol Res. 2007; 39:249. [PubMed: 17917069]
14. Shoaf-Sweeney KD, Hutkins RW. Adv Food Nutr Res. 2009; 55:101. [PubMed: 18772103]
15. Fukuta S, Magnani JL, Twiddy EM, Holmes RK, Ginsburg V. Infect Immun. 1988; 56:1748. [PubMed: 3290106]
16. Jobling MG, Holmes RK. Infect Immun. 2002; 70:1260. [PubMed: 11854209]
17. Iwamori M, Takamizawa K, Momoeda M, Iwamori Y, Taketani Y. Glycoconj J. 2008; 25:675. [PubMed: 18498052]
18. Smit H, Gaastra W, Kamerling JP, Vliegthart JF, de Graaf FK. Infect Immun. 1984; 46:578. [PubMed: 6150011]
19. Campanero-Rhodes MA, Smith A, Chai W, Sonnino S, Mauri L, Childs RA, Zhang Y, Ewers H, Helenius A, Imberty A, Feizi T. J Virol. 2007; 81:12846. [PubMed: 17855525]
20. Hakomori S. Proc Natl Acad Sci U S A. 2002; 99:225. [PubMed: 11773621]
21. Song X, Lasanajak Y, Xia B, Heimbürg-Molinaro J, Rhea JM, Ju H, Zhao C, Molinaro RJ, Cummings RD, Smith DF. Nat Meth. 2011; 8:85.
22. Schnaar RL. Methods Enzymol. 1994; 230:348. [PubMed: 8139508]
23. Song X, Smith DF, Cummings RD. Anal Biochem. 2012; 429:82. [PubMed: 22776091]
24. Arigi E, Blixt O, Buschard K, Clausen H, Lavery SB. Glycoconj J. 2012; 29:1. [PubMed: 22102144]
25. Mulloy, B., Hart, DA., Stanley, P. Essentials of Glycobiology. 2nd. Varki, A.Cummings, RD.Esko, JD.Freeze, HH.Stanley, P.Bertozzi, CR.Hart, GW., Etzler, ME., editors. Cold Spring Harbor Laboratory Press; 2008. p. 661Chapter 47
26. Ando H, Ishida H, Kiso M. Methods Enzymol. 2010; 478:521. [PubMed: 20816497]
27. Wang Z, Gilbert M, Eguchi H, Yu H, Cheng J, Muthana S, Zhou L, Wang PG, Chen X, Huang X. Adv Synth Catal. 2008; 350:1717. [PubMed: 20305750]
28. Jeon I, Iyer K, Danishefsky SJ. J Org Chem. 2009; 74:8452. [PubMed: 19874068]
29. Burkhart F, Zhang Z, Wacowich-Sgarbi S, Wong CH. Angew Chem Int Ed Engl. 2001; 40:1274. [PubMed: 11301448]
30. Su DM, Eguchi H, Yi W, Li L, Wang PG, Xia C. Org Lett. 2008; 10:1009. [PubMed: 18254640]
31. Blixt O, Vasilu D, Allin K, Jacobsen N, Warnock D, Razi N, Paulson JC, Bernatchez S, Gilbert M, Wakarchuk W. Carbohydr Res. 2005; 340:1963. [PubMed: 16005859]
32. Sauerzapfe B, Krennek K, Schmiedel J, Wakarchuk WW, Pelantova H, Kren V, Elling L. Glycoconj J. 2009; 26:141. [PubMed: 18758940]
33. Yu H, Chen X. Org Biomol Chem. 2016; 14:2809. [PubMed: 26881499]

34. Vyas AA, Schnaar RL. *Biochimie*. 2001; 83:677. [PubMed: 11522397]
35. Yu, RK., Saito, M. *Neurobiology of glycoconjugates*. Margolis, RU., Margolis, RK., editors. New York: Plenum Press; 1989. p. 1-42.1989
36. Turton K, Chaddock JA, Acharya KR. *Trends Biochem Sci*. 2002; 27:552. [PubMed: 12417130]
37. Mocchetti I. *Cell Mol Life Sci*. 2005; 62:2283. [PubMed: 16158191]
38. Nashar TO, Betteridge ZE, Mitchell RN. *Int Immunol*. 2001; 13:541. [PubMed: 11282993]
39. Kolter T, Sandhoff K. *Biochim Biophys Acta*. 2006; 1758:2057. [PubMed: 16854371]
40. Cheresh DA, Varki AP, Varki NM, Stallcup WB, Levine J, Reisfeld RA. *J Biol Chem*. 1984; 259:7453. [PubMed: 6203895]
41. Hitoshi S, Kusunoki S, Kon K, Chiba A, Waki H, Ando S, Kanazawa I. *J Neuroimmunol*. 1996; 66:95. [PubMed: 8964919]
42. Song Y, Kitajima K, Inoue S, Inoue Y. *J Biol Chem*. 1991; 266:21929. [PubMed: 1939215]
43. Song Y, Kitajima K, Inoue S, Muto Y, Kasama T, Handa S, Inoue Y. *Biochemistry*. 1993; 32:9221. [PubMed: 8369289]
44. Song Y, Kitajima K, Inoue S, Khoo KH, Morris HR, Dell A, Inoue Y. *Glycobiology*. 1995; 5:207. [PubMed: 7540078]
45. Qu S, Barrett-Wilt G, Fonseca LM, Rankin SA. *J Dairy Sci*. 2016; 99:5083. [PubMed: 27085416]
46. Jahan M, Wynn PC, Wang B. *J Dairy Sci*. 2016; 99:8431. [PubMed: 27423948]
47. Smirnova GP, Kochetkov NK, Sadovskaya VL. *Biochim Biophys Acta*. 1987; 920:47. [PubMed: 3593756]
48. Muralikrishna G, Reuter G, Peter-Katalinic J, Egge H, Hanisch FG, Siebert HC, Schauer R. *Carbohydr Res*. 1992; 236:321. [PubMed: 1291056]
49. Bulai T, Bratosin D, Pons A, Montreuil J, Zanetta JP. *FEBS Lett*. 2003; 534:185. [PubMed: 12527384]
50. Furuya S, Irie F, Hashikawa T, Nakazawa K, Kozakai A, Hasegawa A, Sudo K, Hirabayashi Y. *J Biol Chem*. 1994; 269:32418. [PubMed: 7528216]
51. Yu H, Huang S, Chokhawala H, Sun M, Zheng H, Chen X. *Angew Chem Int Ed Engl*. 2006; 45:3938. [PubMed: 16721893]
52. Yu H, Cheng J, Ding L, Khedri Z, Chen Y, Chin S, Lau K, Tiwari VK, Chen X. *J Am Chem Soc*. 2009; 131:18467. [PubMed: 19947630]
53. Yu H, Chokhawala H, Karpel R, Yu H, Wu B, Zhang J, Zhang Y, Jia Q, Chen X. *J Am Chem Soc*. 2005; 127:17618. [PubMed: 16351087]
54. Yu H, Yu H, Karpel R, Chen X. *Bioorg Med Chem*. 2004; 12:6427. [PubMed: 15556760]
55. Yu H, Lau K, Li Y, Sugiarto G, Chen X. *Curr Protoc Chem Biol*. 2012; 4:233. [PubMed: 25000293]
56. Yu H, Cao H, Tiwari VK, Li Y, Chen X. *Bioorg Med Chem Lett*. 2011; 21:5037. [PubMed: 21592790]
57. Gilbert M, Karwaski MF, Bernatchez S, Young NM, Taboada E, Michniewicz J, Cunningham AM, Wakarchuk WW. *J Biol Chem*. 2002; 277:327. [PubMed: 11689567]
58. Chen X, Fang J, Zhang J, Liu Z, Shao J, Kowal P, Andreana P, Wang PG. *J Am Chem Soc*. 2001; 123:2081. [PubMed: 11456841]
59. Sugiarto G, Lau K, Qu J, Li Y, Lim S, Mu S, Ames JB, Fisher AJ, Chen X. *ACS Chem Biol*. 2012; 7:1232. [PubMed: 22583967]
60. Nojiri H, Kitagawa S, Nakamura M, Kirito K, Enomoto Y, Saito M. *J Biol Chem*. 1988; 263:7443. [PubMed: 2836383]
61. Mizuguchi S, Nishiyama N, Iwata T, Nishida T, Izumi N, Tsukioka T, Inoue K, Kameyama M, Suehiro S. *Ann Thorac Surg*. 2007; 83:216. [PubMed: 17184666]
62. Ratei R, Karawajew L, Schabath R, Ehrfeldt A, Grunert F, Ludwig WD. *Int J Hematol*. 2008; 87:137. [PubMed: 18299959]
63. Julien S, Ivetic A, Grigoriadis A, QiZe D, Burford B, Sproviero D, Picco G, Gillett C, Papp SL, Schaffer L, Tutt A, Taylor-Papadimitriou J, Pinder SE, Burchell JM. *Cancer Res*. 2011; 71:7683. [PubMed: 22025563]

64. Yu H, Lau K, Thon V, Autran CA, Jantscher-Krenn E, Xue M, Li Y, Sugiarto G, Qu J, Mu S, Ding L, Bode L, Chen X. *Angew Chem Int Ed Engl*. 2014; 53:6687. [PubMed: 24848971]
65. Yi W, Liu X, Li Y, Li J, Xia C, Zhou G, Zhang W, Zhao W, Chen X, Wang PG. *Proc Natl Acad Sci U S A*. 2009; 106:4207. [PubMed: 19251666]
66. Utskarpen A, Massol R, van Deurs B, Lauvrak SU, Kirchhausen T, Sandvig K. *PLOS One*. 5:e10944.
67. Lingwood CA, Binnington B, Manis A, Branch DR. *FEBS Lett*. 1879; 584
68. Adlercreutz D, Weadge JT, Petersen BO, Duus JO, Dovichi NJ, Palcic MM. *Carbohydr Res*. 345:1384.
69. Bekri S, Lidove O, Jaussaud R, Knebelmann B, Barbey F. *Cardiovasc Hematol Agents Med Chem*. 2006; 4:289. [PubMed: 17073606]
70. Bremer EG, Levery SB, Sonnino S, Ghidoni R, Canevari S, Kannagi R, Hakomori S. *J Biol Chem*. 1984; 259:14773. [PubMed: 6501317]
71. Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI. *Proc Natl Acad Sci U S A*. 1999; 96:5710. [PubMed: 10318949]
72. Gilewski T, Ragupathi G, Bhuta S, Williams LJ, Musselli C, Zhang XF, Bornmann WG, Spassova M, Bencsath KP, Panageas KS, Chin J, Hudis CA, Norton L, Houghton AN, Livingston PO, Danishefsky SJ. *Proc Natl Acad Sci U S A*. 2001; 98:3270. [PubMed: 11248068]
73. Slovin SF, Ragupathi G, Fernandez C, Jefferson MP, Diani M, Wilton AS, Powell S, Spassova M, Reis C, Clausen H, Danishefsky S, Livingston P, Scher HI. *Vaccine*. 2005; 23:3114. [PubMed: 15837210]
74. Slovin SF, Ragupathi G, Fernandez C, Diani M, Jefferson MP, Wilton A, Kelly WK, Morris M, Solit D, Clausen H, Livingston P, Scher HI. *Cancer Immunol Immunother*. 2007; 56:1921. [PubMed: 17619878]
75. Chen X, Zhang J, Kowal P, Liu Z, Andreana PR, Lu Y, Wang PG. *J Am Chem Soc*. 2001; 123:8866. [PubMed: 11535100]
76. Liu Z, Lu Y, Zhang J, Pardee K, Wang PG. *Appl Environ Microbiol*. 2003; 69:2110. [PubMed: 12676690]
77. Fang J, Li J, Chen X, Zhang Y, Wang J, Guo Z, Zhang W, Yu L, Brew K, Wang PG. *J Am Chem Soc*. 1998; 120:6635.
78. Shao J, Zhang J, Kowal P, Wang PG. *Appl Environ Microbiol*. 2002; 68:5634. [PubMed: 12406759]
79. Shao J, Zhang J, Kowal P, Lu Y, Wang PG. *Biochem Biophys Res Commun*. 2002; 295:1. [PubMed: 12083757]
80. Muthana MM, Qu J, Li Y, Zhang L, Yu H, Ding L, Malekan H, Chen X. *Chem Commun*. 2012; 48:2728.
81. Haverkamp J, van Halbeek H, Dorland L, Vliegthart JF, Pfeil R, Schauer R. *Eur J Biochem*. 1982; 122:305. [PubMed: 7060578]
82. Soh CP, Donald AS, Feeney J, Morgan WT, Watkins WM. *Glycoconj J*. 1989; 6:319. [PubMed: 2535492]
83. Sabesan S, Paulson JC. *J Am Chem Soc*. 1986; 108:2068.
84. Zhang J, Kowal P, Fang J, Andreana P, Wang PG. *Carbohydr Res*. 2002; 337:969. [PubMed: 12039536]
85. Fang JW, Li J, Chen X, Zhang YN, Wang JQ, Guo ZM, Zhang W, Yu LB, Brew K, Wang PG. *J Am Chem Soc*. 1998; 120:6635.

Scheme 1.

Sequential One-Pot Multienzyme (OPME) Synthesis of Ganglio-, Lacto-/Neolacto-, and Globo-/Isoglobo-Series Glycosphingolipid Glycans.

Scheme 2.

Production of GM3 and GD3 Glycans Using OPME α2-3- and α2-8-Sialylation Systems.

Scheme 3.

Synthesis of GM2/GD2 and GM1/GD1b Glycans Containing Neu5Ac, Neu5Gc, Kdn, or Neu5Ac8OMe via One-Pot Multienzyme (OPME) GalNAc and Gal Transfer Systems, Respectively.

Scheme 4.

Synthesis of Lc₃, LNnT, and Sialylated LNnT using OPME Glycosylation Systems.

Scheme 5.
 Synthesis of Sialylated LNT Using OPME Sialylation Systems.

Scheme 6.
Synthesis of Le^x Pentasaccharide and Its Sialylated Forms using OPME Glycosylation Systems.

Scheme 7.

OPME Synthesis of Globo and Isoglobo-Series Glycans.